Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies

Theodoros P. Vassilakopoulos, John V. Asimakopoulos, Kostas Konstantopoulos and Maria K. Angelopoulou

Abstract: The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has improved considerably in recent years owing to the approval of highly active novel agents such as brentuximab vedotin and Programmed Death-1 (PD-1) inhibitors. Although no randomized trials have been conducted to provide formal proof, it is almost undisputable that the survival of these patients has been prolonged. As autologous stem-cell transplantation (SCT) remains the standard of care for second-line therapy of most patients with rr-cHL, optimization of second-line regimens with the use of brentuximab vedotin, or, in the future, checkpoint inhibitors, is promising to increase both the eligibility rate for transplant and the final outcome. The need for subsequent therapy, and especially allogeneic SCT, can be reduced with brentuximab vedotin consolidation for 1 year, while pembrolizumab is also being tested in this setting. Several other drug categories appear to be active in rr-cHL, but their development has been delayed by the appearance of brentuximab vedotin, nivolumab and pembrolizumab, which have dominated the field of rr-cHL treatment in the last 5 years. Combinations of active drugs in chemo-free approaches may further increase efficacy and hopefully reduce toxicity in rr-cHL, but are still under development.

Keywords: brentuximab vedotin, Hodgkin lymphoma, nivolumab, pembrolizumab, PET, PET/CT, refractory, relapsed

Received: 3 May 2019; revised manuscript accepted: 18 December 2019.

Introduction

Hodgkin lymphoma (HL) is a relatively common B-cell malignancy with an annual incidence of ~2–3 per 100,000, accounting for ~10% of all lymphomas and <1% of all malignancies. The median age at diagnosis depends on the population analysed (clinical trials, retrospective series or population-based), with 10–20% of cases diagnosed after the age of 60 in most published series. However, the median age is highest (35–45 years) in SEER or UK population data, where the frequency of older age (>60 years) may exceed 20% or even 30%.1–3 The disease is characterised histologically by a minority of bi- or multinucleated or large mononuclear neoplastic cells, known as Reed-Sternberg and Hodgkin cells, respectively, and collectively called HRS cells, admixed with an abundant reactive nontumoral inflammatory microenvironment.4 Based on morphology and immunohistochemistry, HL is subdivided into classical HL (cHL) and nodular lymphocyte-predominant HL (NLPHL), with ~95% of the cases falling into the broad category of cHL, which is discussed in this review.5

With the advent of effective multiagent chemotherapy combinations, with or without radiotherapy (RT), during the past 50 years, HL has been transformed from a highly fatal to a highly curable disease.6,7 Further to targeting neoplastic cells, the nontumoral microenvironment also provides important therapeutic targets with clinical implications.
Summary of current first-line therapy in cHL

In localized stages without adverse prognostic factors (early stages), brief courses (two to three cycles) of adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy followed by involved-field or involved-node radiotherapy (IFRT, INRT) produce very satisfactory results,8–11 with indicative 10-year progression-free survival (PFS) and 10-year overall survival (OS) rates of 87% and 94%, respectively.10 The results are also satisfactory in localized stages with risk factors (intermediate stages) with four cycles of ABVD plus IF(IN)-RT,11–14 with PFS and OS of at least 83% and 91% at 10 years, respectively.10,14 Intensification with two cycles of BEACOPP-escalated plus ABVDx2 and RT improves disease control, but not OS.13 Early response assessment with positron emission tomography (PET) after two ABVD cycles (interim PET; iPET) may permit the omission of RT, and probably reduces long-term toxicity in patients with a strictly negative iPET, defined by the 2007 International Harmonization Project criteria and roughly corresponding to a Deauville 5-point scale (D5PS) score of 1 or 2. Omission of RT is associated with minimal compromise in disease control and no detrimental effect on OS, especially in intermediate stages treated solely with six ABVD cycles.15 In early favorable stages (or nonbulky IA/IIA), the 5-year PFS after two, three, or four cycles of ABVD alone was approximately 86%, 87% and 90%, respectively.15–17 Similar results were reported in real-life by the British Columbia group.18 Furthermore, 12–25% of patients who remain iPET-positive after ABVDx2 may enjoy better disease control, and probably increased survival, with the addition of two cycles of BEACOPP-escalated instead of two ABVD cycles prior to RT.9,15,18 However, it appears that this benefit is restricted largely to the subset of iPET-positive patients who have more intense uptake with D5PS 4–5.19

In advanced stages, six to eight cycles of ABVD plus RT in a selected minority of patients can produce 10-year PFS rates of 65–75% and a 10-year OS exceeding 80%.20–27 The current trend is to adopt six cycles of ABVD, especially in the PET era. The German Hodgkin Study Group (GHSG) standard of care is six cycles of BEACOPP-escalated, which has produced better results (disease control and OS 84% and 90% at 10 years) and minimized the use of RT at the expense of higher toxicity.28–31 The introduction of iPET in order to avoid bleomycin in case of negative results (defined as D5PS 1-3) and switch to BEACOPP-escalated only in the minority of patients who remain PET-positive (D5PS 4-5) after ABVDx2, may improve the outcome of fixed ABVD chemotherapy.24,32–34 Indeed, the omission of bleomycin after two cycles of ABVD in early unfavorable and advanced HL in the RATHL trial was not inferior to the continuation with full ABVD for six cycles in total.32 However, the negative predictive value of iPET after ABVDx2 appears to be suboptimal.24,35,36 The reverse strategy, which starts with two cycles of BEACOPP-escalated and step down to ABVDx4, or only two further cycles of BEACOPP-escalated, keeping the whole six cycles only for iPET positive patients (defined here as D5PS 3–5), appears also highly effective.37–39

Recently, the introduction of brentuximab vedotin (BV) in combination with AVD, thus replacing bleomycin, was shown to improve disease control in stage III/IV cHL with minimization of lung toxicity. In the whole patient population, the 2-year modified PFS per the Independent Review Committee (IRC) was 82.1% versus 77.2% for BV-AVD and ABVD, respectively (hazard ratio 0.77, p = 0.03),40 and the benefit appeared to be durable in the 3-year follow-up report.41 Interestingly, increases in modified PFS by 7–9% with a ~4% increase in short-term OS were observed in high-risk subgroups, such as stage IV or any, and particularly multiple, extranodal involvement.42 Following United States Food and Drug Administration (FDA) approval of BV-AVD for advanced cHL, and based on the above data on preplanned subgroup analyses, the European Medicines Agency (EMA) also approved the combination of BV-AVD for patients with stage IV cHL.40,42,43 Further to incorporation into the AVD regimen, the GHSG has also evaluated the incorporation of BV into a BEACOPP backbone. Among the BrECAPP and BrECADD regimens (BV, etoposide, cyclophosphamide, doxorubicin and procarbazine/prednisone or dacarbazine/dexamethasone), the latter was considered equally effective and less toxic in a randomised phase II trial.44 Thus, BrECADD was selected to be compared with the GHSG standard of care of six cycles of BEACOPP-escalated in the HD21 trial for advanced cHL.45

Despite these exciting results, 20–30% of patients will progress or relapse within 10 years of...
ABVD-based strategies, while this figure will be clearly lower with iPET- and BEACOPP-based strategies. In addition, recent data show that patients who remain in remission after 5 years from diagnosis have an almost linear incidence of very late relapses for at least an additional 20 years. Thus, a considerable proportion of patients will develop relapsed/refractory cHL (rr-cHL) and require second-line salvage therapy, which will be curative in roughly half of them.

This review will focus on second and subsequent lines of therapy for rr-cHL, the strategies that might improve the efficacy of second-line therapy and the optimal integration of novel agents and high-dose therapy (HDT) with autologous (autoSCT) or allogeneic stem-cell transplantation (alloSCT) in the treatment algorithm.

Second-line therapy for classical Hodgkin lymphoma
Following frontline treatment failure, the majority of patients with rr-cHL require systemic treatment. Local/regional salvage RT can cure a minority of patients, who experience asymptomatic, localised relapse outside the previous RT field, especially if relapse occurs > 1 year after the end of treatment. Among the vast majority of patients requiring systemic therapy, most are eligible for intensive salvage chemotherapy with HDT and autoSCT. However, a minority, those aged > 65–70 years or with serious comorbidities as well as the rare poor mobilizers, are not candidates for autoSCT. These patients are treated with second-line, usually noncross-resistant regimens, but generally have a poor prognosis when treated with conventional chemotherapy.

Patients with relapsed/refractory classical Hodgkin lymphoma eligible for autoSCT
Standard salvage therapy and prognostic factors.

Chemotherapy options. Based on the results of two randomized trials, HDT/autoSCT is considered the standard of care for eligible patients with rr-cHL who remain chemosensitive to second-line regimens. HDT/autoSCT is also the standard of care for chemorefractory patients with stable disease (SD), but second-line salvage chemotherapy is almost futile in patients with progressive disease (PD). Platinum or gemcitabine-based regimens are usually administered as salvage therapy with the aim to assess chemosensitivity, achieve an acceptable remission status, and mobilise and collect peripheral blood stem-cells. Although many regimens have been evaluated in this setting (Table 1), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), ESHAP (etoposide, methylprednisolone, high-dose cytarabine, cisplatin), DHAP (dexamethasone, high-dose cytarabine, cisplatin), ICE (ifosfamide, carboplatin, etoposide), GDP (gemcitabine, dexamethasone, cisplatin), GVD (gemcitabine, vinorelbine, dexamethasone) or similar regimens are the most commonly used, while mini-BEAM (carmustine, etoposide, cytarabine, melphalan) and Dexa-BEAM (dexamethasone- BEAM) are much less popular because of excessive toxicity.

Although the actual dose intensity of DHAP may affect prognosis, further treatment intensification with the addition of alternating higher-dose cytotoxic agents between salvage therapy with DHAP and HDT did not improve the outcome of HDT/autoSCT. In clinical practice, we prefer IGEV because of less myelotoxicity and an excellent mobilisation potential, but any of the above regimens is equally acceptable, since no proven superiority has been demonstrated over the others. The results of these salvage regimens are shown in Table 1 and suggest that a considerable percentage of patients with rrHL, up to 30%, will not be directly eligible for HDT/autoSCT after second-line salvage therapy due to the lack of chemosensitivity. Furthermore, the percentages of complete response (CR) to conventional second-line salvage therapy are rather low.

Who is eligible for autoSCT: conventional or functional imaging? In addition to chemosensitivity evaluated by conventional restaging, PET/CT after salvage therapy is also a powerful prognostic factor for the outcome of autoSCT. Patients with a negative PET following salvage therapy have very good outcomes, at least in the short term, with relapse rates generally not exceeding 15–30%. Patients who remain PET-positive have significantly inferior prognosis; however, they still have a 25–40% chance of cure, especially if they do not have PD based on conventional restaging criteria. Therefore, autoSCT should not be omitted or withheld based solely on the persistence of metabolically active disease. In addition to PET-based response to salvage therapy, the baseline FDG-PET metabolic tumor volume prior to salvage therapy can provide independent prognostic information.
A major question is whether PET-positive, but conventionally responding, patients should be forwarded to HDT/autoSCT, or if further effort to achieve PET negativity should be made. Moskowitz and colleagues showed that, if a PET-negative status is achieved by a second salvage regimen (3rd-line treatment), the outcome of HDT/autoSCT is equally good with cases who directly achieve PET negativity with the first salvage regimen. However, it is not clear whether the effort to achieve PET-negativity with 3rd-line therapy is beneficial per se or whether it is just a means of selecting patients with a higher chance of cure after HDT/autoSCT. Summarising, chemosensitive patients based on conventional imaging, and those with SD after salvage therapy, can be forwarded to HDT/autoSCT, while those with PD have a very low chance of benefiting from the procedure. Further handling of PET-positive patients without conventionally defined PD depends on the practice of each centre. Both immediate transplant and further salvage to improve remission status are acceptable. D5PS grading may predict prognosis and facilitate treatment decisions but needs prospective evaluation. However, with the potential incorporation of novel agents in earlier treatment lines in the near future, the main goal of salvage therapy will be PET negativity prior to HDT/autoSCT.

**Table 1. Conventional salvage regimens in relapsed/refractory Hodgkin lymphoma.**

| Chemotherapeutic regimen | Author | # Pts | OR % | CR% | Survival outcome | % pts PBSC mobilization |
|--------------------------|--------|-------|------|-----|----------------|------------------------|
| Intensive | DEXA-BEAM | Schmitz $^{51}$ | 44  | 81  | 27  | 34% (3 year FFTF) | NR |
| | Mini-BEAM | Linch $^{55}$ | 20  | 73  | 41  | 35% (3-year DFS) | NR |
| Containing platinum | ESHAP | Aparicio $^{59}$ | 22  | 70  | 34  | 36% (4-year EFS) | NR |
| | ASHAP | Rodriguez $^{44}$ | 56  | 88  | 26  | 58% (43-month DFS) | NR |
| | DHAP | Josting $^{62}$ | 281 | NR  | 72  | 62% (3-year FFTF) | NR |
| Containing Ifosfamide | ICE | Moskowitz $^{65}$ | 65  | 88  | 26  | 58% (43-month DFS) | 96.9% |
| | IVOx | Sibon $^{66}$ | 34  | 76  | 32  | 63% (5-year EFS) | 90% |
| Containing Gemcitabine | GDP | Baetz $^{67}$ | 23  | 69  | 17  | NR | 100% |
| | GEM-P | Chau $^{68}$ | 21  | 80  | 24  | 40.4% (1-year PFS) | 15% |
| | IGEV | Santoro $^{58}$ | 91  | 81  | 54  | NR | 98.7% |
| Others | Bendamustine | Moskowitz $^{69}$ | 18  | 75  | 38  | NR | NR |

ASHAP, (adriamycin, solumedrol, high-dose cytarabine, cisplatin); CR, complete response; Dexa-BEAM, dexamethasone-BEAM; DHAP, (dexamethasone, high-dose cytarabine, cisplatin); DFS, disease-free survival; EFS, event-free survival; ESHAP, (etoposide, methylprednisolone, high-dose cytarabine, cisplatin); FF2F, freedom from second failure; FFTF, freedom from treatment failure; GDP, (gemcitabine, dexamethasone, cisplatin); GEM-P, cisplatin and methylprednisolone; ICE, (ifosfamide, carboplatin, etoposide); IGEV, (ifosfamide, gemcitabine, vinorelbine, prednisone); mini-BEAM, (carmustine, etoposide, cytarabine, melphalan); NR, not reported; OS, overall survival; OR, overall response; PBSC, peripheral blood stem cell; pts, patients; PFS, progression-free survival.
been reported to affect the outcome of HDT/autoSCT.86 Recently, the RisPACT consortium evaluated potential risk factors for the outcome of autoSCT in 546 patients. In multivariate analysis, CR duration $\leq 3$ months, stage IV, a nodal lesion $> 5$ cm, Eastern Cooperative Oncology Group performance status (ECOG PS) $\geq 1$ and inadequate response to salvage therapy prior to autoSCT assessed by CT or PET, were independent predictors for PFS.87

Optimizing second-line therapy in relapsed/refractory classical Hodgkin lymphoma. More effective salvage regimens and incorporation of novel agents into second-line salvage regimens might improve either the proportion of patients who can be forwarded to HDT/autoSCT, or even the outcome of autoSCT, by increasing response rates and the depth of remission. In chemorefractory patients, who are not eligible for autoSCT, novel agents may induce responses and allow a potentially curative transplant. Finally, consolidation strategies after autoSCT might be optimized in terms of either patient selection or evaluation of other novel agents.

New conventional salvage chemotherapy regimens. Bendamustine monotherapy is active in rr-cHL following autoSCT or ineligible for the procedure, with overall response rates (ORR) 50–60% and CR rates of $\sim 30\%$, but very few patients remain progression-free at 2 years.88–90 Bendamustine is also active after both autoSCT and BV failure,91–93 and can serve as a bridge to alloSCT.91,92 More recently, the BeGEV (bendamustine, gemcitabine, vinorelbine) combination was studied as second-line treatment with very promising outcomes: the ORR was 83% with 73% CRs; 97% of patients underwent successful stem-cell collection. On an intention-to-treat basis, the transplant rate was 73%. The 2-year PFS and OS rates were 80.8% and 89.3%, respectively, for those patients who proceeded to autoSCT, making this combination a very promising approach.94

Finally, GemOx (gemcitabine, oxaliplatin) is a novel combination for rr-HL,95 which may be active both in the setting of platinum-based salvage therapy and after autoSCT failure.96

Incorporation of novel agents in second-line salvage therapy. This strategy is currently restricted to the incorporation of BV in second-line strategies, as summarized in Table 2.99–110 Other combinations, such as bortezomib-ICE, panobinostat-ICE and bortezomib-IGEV, were evaluated but were not further developed, with both bortezomib-based combinations failing to prove superior to the corresponding conventional regimens in randomised phase II trials.76,97,98

Two approaches have been adopted with BV given either sequentially or concurrently with established salvage regimens.99–107,111–115 All but one of the phase II trials of BV plus conventional chemotherapy included notably similar numbers of patients, ranging from 57 to 65.99–105 Sequential strategies include BV induction, either as two cycles of dose-dense weekly 1.2 mg/kg BV infusions on days 1, 8, and 15, every 28 days,99,100 or two to four standard dose 1.8 mg/kg BV infusions every 3 weeks.101–103 If metabolic CR was not achieved in these studies, patients received either augmented ICE,99,100 or various established salvage regimens.101–103 Concurrent strategies included the combination of BV with ESHAP (BrESHAP),104 DHAP (BV-DHAP),105,113 or ICE.106,107 In all studies, PET-based rather than conventional response criteria were used.116,117 BV has also been combined with gemcitabine, nivolumab, or bendamustine, as will be analyzed later.108,110,114,115 In a recent retrospective trial, the combination of BV with IGEV in rr-cHL patients (half of them receiving it as a subsequent salvage line) led to a more favorable SCT outcome by improving metabolic status prior to SCT in this high-risk clinical setting.109

The results of all phase II trials of BV plus sequential or concurrent established salvage regimens are summarized in Table 2. Almost all these trials provided high metabolic CR rates, typically 70–80%, which appear higher than those achieved with the corresponding salvage regimens without BV.99–105 In addition, minimizing the incidence of PD, they reproducibly demonstrated high SCT rates, with 87–100% of the patients ultimately undergoing autoSCT, which also appears clearly better than the rates achieved with conventional salvage therapy.99–105 In intention-to-treat analyses, the 2- or 3-year PFS rates were $> 70\%$ and up to 80%, respectively.99–106

The sequential strategies also demonstrated that a brief BV monotherapy can induce metabolic CRs in 25–35% of rr-cHL as second-line therapy, thus enabling HDT/autoSCT without further
### Table 2. Summary of clinical trials combining BV with salvage regimens used to mobilize stem cells prior to autoSCT either in sequential or concurrent design.

| Author            | Regimen                                         | Pts (#) | Median age (range) | Primary refr (%) | CR definition | ORR (%) | CMR (%) | ASCT performed (%) | P(E)FS       |
|-------------------|-------------------------------------------------|---------|--------------------|------------------|---------------|----------|----------|---------------------|---------------|
| Moskowitz         | BVx2\(^a\) plus AugIce if no CMR              | 45      | 31 (13–65)         | 56               | D5PS 1-2      | NR       | 27 to BV 76 to both\(^f\) | 98\(^f\) 80% at 3 years |
| Moskowitz         | BVx3\(^a\) plus AugIce if no CMR              | 20      | 35 (19–59)         | 45               | D5PS 1-2      | NR       | 30 to BV 80 to both  | 100          | 85% at 2 years   |
| Chen101; Herrera  | BVx2-4\(^c\) plus chemo if no CMR             | 37      | 34 (11–67)         | 65               | Per Cheson\(^116\) | 68 to BV (25/37) | 35 to BV 75 to both\(^g\) | 92\(^i\) 72% at 2 years\(^k\) |
| Herrera           | BVx4\(^d\) plus additional Tx at physician’s discretion | 20      | 25 (15–57)         | 60               | Per Cheson\(^116\) | 75 to BV (15/20) | 50 to BV 70 to both | 90 (18/20) NR |
| Garcia-Sanz       | BrESHAP x3 + BV x1 plus consBV x3              | 66      | 36 (18–66)         | 61               | Per Cheson\(^116\) | 91       | 70\(^h\) 91       | 71% at 2.5 years |
| Hagenbeek         | BV-DHAP x3                                     | 61      | 29 (19–71)         | 38 (no CR)       | NR            | 87       | 79       | 87                  | 76% at 2 years   |
| Cassaday          | BV-ICE x2\(^e\)                                | 16      | 32 (23–60)         | 69 (no CR)       | Per Cheson\(^116\) | 94       | 88       | 75                  | 19% relapses at medfup 6.5 months |
| Stamatoullas      | BV-ICE x 2-3                                   | 39      | 30 (18–65)         | NR               | D5PS 1-3      | 95       | 69       | 20                  | 69% at 12 months |
| Cole              | BV-Gemcitabine                                  | 46      | 17.6 (5.4–18.7)    | 29 (64%)         | D5PS 1-2      | 74       | 67       | 34                  | NR            |
| Abuelgasim        | BV-IGEV + post-SCT BV consolidation             | 28      | 25 (14–49)         | NR               | D5PS 1-3      | 95       | 71       | NR Post-SCT; 87.1% at 2 years | |
| Herrera           | BV-Nivo                                        | 62      | 36 (18–69)         | 45               | Per Lugano\(^173,174\) | 83       | 50\(^i\) 89\(^j\) | 89% at 6 months |

ASCT, autologous stem-cell transplantation; AugIce, augmented ICE; BV, brentuximab vedotin; CMR, complete metabolic response; CR, complete response; D5PS, Deauville 5-point scale; DHAP, (dexamethasone, high-dose cytarabine, cisplatin); EFS, event-free survival; ICE, (ifosfamide, carboplatin, etoposide); IF-RT, involved-field radiation therapy; IGEV, (ifosfamide, gemcitabine, vinorelbine, prednisone); LFU, lost to follow up; medfup, medium follow up; Nivo, nivolumab; NR, not reported; ORR, overall response rates; PET, positron emission tomography; PFS, progression-free survival; PR, partial response; SCT, stem-cell transplantation; SD, stable disease.

\(^a\)Reference 109 represents a retrospective analysis. All the other presented studies are prospective.

\(^b\)BV 1.2 mg/kg on days 1, 8, and 15 of each cycle.

\(^c\)Standard BV cycles 1.8 mg/kg every 21 days.

\(^d\)Escalated to 2.4 mg/kg every 21 days if no CMR achieved with two standard 21-day cycles at 1.8 mg/kg.

\(^e\)BV 1.5 mg/kg on days 1 and 8 combined with ICE every 21 days.

\(^f\)80% (36/45) if D5PS score 3 considered as CR. A single patient LFU after a positive PET with BVx2.

\(^g\)Five additional patients were forwarded to autoSCT directly after BV with a positive PET (4 PR, 1 SD with IF-RT).

\(^h\)76% if D5PS score 3 considered as CR (similar outcomes for D5PS scores 3 and 2).

\(^i\)60% if D5PS score 3 considered as CR.

\(^j\)Including 2 patients who received alloSCT for PR and SD after chemo.

\(^k\)Only the 32/37 patients who received autoSCT were included (80% for those transplanted after BV only).

\(^l\)42 patients proceeded to autoSCT after BV+Nivo and 12 after additional salvage therapy.
chemotherapy and that the outcome of these autoSCTs is favorable. Furthermore, it was demonstrated that an additional third dose-dense BV cycle, or BV dose escalation to 2.4 mg/kg after the second standard-dose 3-weekly BV infusion are not the way to increase the metabolic CR rate.

Besides the obvious superiority of sequential and concurrent BV-salvage combinations over the corresponding conventional salvage regimens, some limitations should be kept under consideration. The CR rates should be compared with caution (Tables 1 and 2) because PET-based and conventional criteria have been generally applied in different time periods, so that figures may not be comparable. Furthermore, BV-chemotherapy combinations have been evaluated in moderately-sized studies and have not been directly compared with the corresponding traditional salvage regimens, while they have demonstrated relatively higher rates of grade 3–4 hematologic toxicity.

BV has also been evaluated in combination with bendamustine in rr-cHL, although HDT/auto-SCT was not intended for all patients. In a single-center phase I/II trial, LaCasce et al. assessed the efficacy and toxicity of BV 1.8 mg/kg on day 1 plus bendamustine 90 mg/m² on days 1 and 2 of 3-week cycles for up to 6 cycles. Among 55 patients, 53 were evaluable for response: The metabolic ORR was 92% with 74% CRs and response rates were better for relapsed than primary refractory disease; only 1/53 patients had PD. Ultimately, 77% of patients without PD proceeded to HDT/auto-SCT and 60% also received consolidation with BV up to 16 infusions in total. Among 55 patients, 53 were evaluable for response: The metabolic ORR was 92% with 74% CRs and response rates were better for relapsed than primary refractory disease; only 1/53 patients had PD. Ultimately, 77% of patients without PD proceeded to HDT/auto-SCT and 60% also received consolidation with BV up to 16 infusions in total. At a median follow-up of 23 months after auto-SCT, the estimated 2-year PFS and OS were 63% and 94% overall and 70% and 95% for the transplanted patients, many of whom had not age- or comorbidity-related restrictions. Unexpectedly, severe infusion-related reactions (IRRs) were frequently observed. Stem-cell collection was adequate, despite concerns regarding potential detrimental effects of bendamustine. More recently, an international, multicenter phase I/II trial of 68 heavily pretreated rr-HL patients confirmed the applicability of the above dosing regimen to more extensively pretreated patients, who had received a median of 3 prior regimens (range; 1–8) including autoSCT in 57%. Among the 37 patients, who received the optimal dose at the phase II portion, the ORR was 78% and the CR rate 43%. The 2-year PFS and OS exceeded 60% and 80% respectively. Both the latter studies suggest that BV-bendamustine could potentially replace platinum- or gemcitabine-based chemotherapy before autoSCT in transplant-eligible patients as an alternative, less (or equally) toxic regimen, given on an outpatient basis. Finally, Cole et al. evaluated the combination of BV with gemcitabine in young adults (≤30 years-old) with primary refractory or early relapsing disease in a single-arm phase I/II trial. The CR rate (Deauville 1-2 on FDG-PET scan) reached 57% allowing a successful and rapid reference to HDT/SCT consolidation.

In the same context, Herrera et al. introduced an almost chemo-free approach, in which BV was combined with the Programmed Death-1 (PD-1) inhibitor nivolumab in the setting of second-line treatment of 62 patients with rr-cHL prior to any further chemotherapy (Table 2). On cycle 1, 1.8 mg/kg BV was administered on day 1 and 3 mg/kg nivolumab on day 8, while for the remaining cycles, 2–4, both agents were given on day 1 at the same doses. Among 60 evaluable patients, the ORR was 84% and the CR rate 62%, with 48% of CR patients achieving a D5PS score <2. Only 8% of patients developed PD. Among 60 patients, 54 (90%) were forwarded to HDC/autoSCT, although 12 did so after additional chemotherapy. Post-autoSCT, nine patients received consolidation with RT, BV, or pembrolizumab (three cases each). The 15-month PFS rate was 82%. Similar results were seen in an additional series of 30 patients who received BV and nivolumab concurrently on day 1 (ORR 93%, CR 80%; 29 proceeded to auto-SCT, 25/29 directly). As a result, the BV-nivolumab combination appears as a chemo-free, potent salvage therapy for rr-cHL patients prior to autoSCT, which can be given on an outpatient basis. A further advantage is that high-cost novel agents are given for a short time period only.

The concept of chemo-free approach incorporating BV and checkpoint inhibitors has also been adopted in patients heavily pretreated with cHL. Diefenbach and colleagues evaluated the combination of nivolumab and BV in 19 heavily pretreated HL patients, with a median of 3 prior therapies, including SCT and BV. The combination was generally well-tolerated, while the ORR...
and CR rate reached 89 and 50%, respectively.\textsuperscript{119} Furthermore, BV has been combined with ipilimumab,\textsuperscript{120} or both nivolumab-ipilimumab.\textsuperscript{121–123} In the recent extended follow-up report, the triplet combination demonstrated higher CR rates and potentially more durable response rates than any doublet combination, at the expense of 8.2% incidence of dose-limiting toxicity as well as deaths secondary to pneumonitis in the nivolumab-containing combinations.\textsuperscript{123}

**Bridging autoSCT with novel agents in chemorefractory patients.** Although the potential future incorporation of BV into second-line regimens may change the clinical landscape, as described above, a considerable proportion of patients are chemorefractory; in particular, those with PD are not deemed eligible for autoSCT with the currently approved conventional salvage regimens. Prior to performing a ‘desperate’ auto-SCT, many physicians try to get a better response with additional chemotherapy.

BV has been evaluated in this setting in retrospective studies.\textsuperscript{124} In a UK-wide retrospective study, 99 patients with a median age of 32 years (range 13–70) received BV as further salvage after two (70%), three (24%) or four (5%) previous lines of treatment.\textsuperscript{125} The outcome of 2nd-line salvage, mainly with platinum- or gemcitabine-based regimens, typically was PD, SD, or PR/partial metabolic response, although 10% of the patients had achieved a CR. The ORR to BV was 56%, with 29% CR/CRu or metabolic CR, and was similar irrespective of the extent of previous treatment. Approximately one-third of patients proceeded directly to auto- or alloSCT; almost all of them had responded, and two-thirds had achieved a CR on BV. An additional 27% did so after further chemotherapy, while 39% failed to undergo SCT, and received only further chemotherapy or no further treatment. Of the 38 latter patients, 10 had actually responded to BV, but the responses were partial and short-lived. The median PFS for the whole population was 5.6 months and the median OS 37.2 months, but was not reached for SCT-treated patients, being similar for those who underwent SCT directly after BV or following further chemotherapy.

The published experience of other groups demonstrates rates of ‘immediate’ SCT ranging from 34% to 47% in all studies but one, thus confirming that BV can overcome chemoresistance and permit a viable SCT in a sizeable proportion of patients ineligible for autoSCT due to being chemorefractory or inadequate response to chemotherapy, as judged by the treating physician.\textsuperscript{124–129}

**Consolidation after autoSCT in high-risk patients.** Once autoSCT has been performed, the risk of further relapse/progression can be as high as 50%.\textsuperscript{130–132} The AETHERA trial demonstrated that disease control can be improved with 16 infusions of BV over placebo every 3 weeks, started 30–45 days after autoSCT, in patients who are deemed to be at high risk of relapse, as reflected by the presence of primary refractory disease or early (<1 year) or extranodal relapse. Based on the analysis of 329 patients, AETHERA met its primary endpoint, with a hazard ratio of 0.57 (95% CI 0.40–0.81; \( p = 0.0013 \)) for PFS per the Independent Review Committee.\textsuperscript{56} In the 5-year follow-up report, the 5-year PFS for BV versus placebo was 59% versus 41% per investigator assessment [hazard ratio 0.52 (95% CI 0.38–0.72)].\textsuperscript{57} Although the formal OS analysis is planned for 2020, the 3-year OS rate exceeded 80%, comparing favorably with historical survival data for high-risk HL patients undergoing autoSCT. However, OS was the same in both arms of AETHERA, with the curves being completely superimposable, probably reflecting the widespread use of BV in 87% of the relapsed patients in the placebo arm upon further progression. Based on AETHERA, BV was approved as consolidation therapy for patients with cHL who have undergone ASCT and are deemed to be at increased risk of relapse. Interestingly, the time to second subsequent therapy was improved by BV: at 5 years, 36% of patients allocated to the BV arm had received at least two subsequent lines of therapy versus 46% in the placebo arm [hazard ratio 0.66 (95% CI 0.47–0.92)]. The use of subsequent alloSCT was similarly decreased in the BV arm (12% versus 21%).

When five potential risk factors were considered, namely initial remission duration <1 year, <CR to most recent salvage therapy, extranodal disease at the time of salvage therapy, B symptoms at the time of salvage and >1 salvage regimen required to achieve chemosensitive disease, hazard ratios for PFS were much lower in favor of BV in patients with at least two or at least three risk factors (0.42 and 0.39, respectively) without any
effect on OS.⁵⁶,⁵⁷ Along these lines, it appears that patients with worse characteristics obtain greater PFS benefit from BV consolidation. Similarly, BV consolidation produced a significant PFS benefit for patients who remained PET positive after salvage therapy, but not for PET-negative patients. However, these data should be interpreted with caution, because AETHERA was designed prior to the widespread use of pretransplant PET; thus almost one-third of the patients did not undergo PET evaluation, which was not mandatory by the protocol, while predefined criteria for PET positivity were not established.⁵⁶

In the increasingly prevalent setting that patients have been forwarded to autoSCT with the use of BV due to being chemorefractory, it appears sensible to administer BV consolidation; however, fewer cycles could be considered (for example ≤10) in order to avoid cumulative toxicity, especially peripheral neuropathy.¹¹¹

Further to the already approved indication of BV consolidation after autoSCT in high-risk patients, other studies are currently investigating consolidation strategies in HL. The trial of panobinostat consolidation was closed prematurely due to low accrual rate. For this reason, efficacy was not formally evaluated, but 29% of patients discontinued due to PD from the placebo arm versus 11% in the panobinostat arm.¹³³ Pembrolizumab 200 mg IV every 3 weeks for up to eight cycles is being tested in a phase II trial as consolidation of auto-SCT in high-risk rr-cHL patients post-ASCT after two to three lines of therapy. At 1.5 years, PFS and OS were 78% and 100%, respectively, for the 30 evaluable patients.¹³⁴

Patients with relapsed/refractory classical Hodgkin lymphoma are ineligible for autoSCT due to age or comorbidities

Standard salvage therapy and prognostic factors. A small minority of younger, fit patients with asymptomatic, nodal-only relapse outside any previous RT field may not be treated with salvage chemotherapy and autoSCT, because they are potentially curable with salvage RT only.⁴⁹ However, a sizeable minority of patients with rr-cHL includes those who are not candidates for autoSCT, either due to their advanced age, or due to the presence of comorbidities or poor performance status. Unfortunately, there are no formal guidelines for the therapeutic approach of such patients, and the results of conventional salvage therapy for elderly patients with rrHL are rather disappointing.⁵³,⁵⁴ As a result, those patients who are ineligible for aggressive chemotherapy followed by HDC/autoSCT, should be treated with the aim of preserving a fragile balance between disease control and therapy-related toxicity. Treatment options for this sensitive population include noncross-resistant chemotherapy, such as ChlVPP (chlorambucil, vinblastine, procarbazine, prednisone) or MOPP (mechlorethamine, vincristine, procarbazine, prednisone), GVD, gemcitabine-vinorelbine, single-agent bendamustine (off-label), or even GDP, similarly to patients with rrHL after autoSCT failure as described below.¹³⁵

Optimizing second-line therapy in rrHL ineligible for autoSCT. The novel agent monotherapy (BV, nivolumab, pembrolizumab) has not been approved as second-line therapy but might be applicable as an off-label option, as also would be BV-bendamustine.¹³⁶ In the BV-bendamustine trial published by LaCasce and colleagues, patients who were not forwarded to autoSCT had acceptable outcomes. Although many of them were not ‘ineligible for SCT’, the BV-bendamustine combination can be a viable second-line option in this population as well.¹¹⁴

Third-line therapy and beyond

Approximately 50% of rr-cHL patients undergoing autoSCT will experience further disease progression or relapse following current salvage regimens.¹³⁰,¹³⁷ The outlook of these patients is very poor, with an estimated median OS of 2–3 years.¹³⁸–¹⁴⁴ In addition, the expected outcome of transplant-ineligible patients, either young but chemorefractory, or elderly, or those with significant comorbidities after 2nd-line failure, is probably even worse. With the availability of BV and checkpoint inhibitors in the above distinct clinical settings where third- or subsequent-line therapy is required, treatment strategies have become similar, though the goal (palliative or curative) differs considerably.

Until recently, the management of patients who failed HDT/autoSCT was largely empirical due to the lack of effective therapeutic options and the absence of prospective clinical trials.¹⁴¹–¹⁴³ Historically, additional chemotherapy used to be
the commonly acceptable practice for relapse after autoSCT, aiming to induce remission. In this setting, eligible chemosensitive patients could receive consolidation with reduced intensity conditioning (RIC) alloSCT (see below). Nevertheless, a significant proportion of patients is not eligible for allo-SCT due to chemoresistant disease, lack of matched donor availability or poor performance status/comorbidities. In the era of BV and checkpoint inhibitors (nivolumab and pembrolizumab) the role of RIC-alloSCT in HL has become a matter of debate among lymphoma physicians, as discussed at the end of this review.

**Brentuximab vedotin as salvage therapy for relapsed/refractory classical Hodgkin lymphoma**

**Brentuximab vedotin in autoSCT failures.** In 2011 and 2012, respectively, BV was approved by the FDA and EMA for either patients with relapsed cHL after autoSCT or those after at least two prior chemotherapy regimens who are not candidates for autoSCT (‘when autoSCT or multiagent chemotherapy is not an option’ according to EMA). In the pivotal phase II study, 102 patients were treated with single-agent BV 1.8 mg/kg every 3 weeks for maximum of 16 cycles. All patients had failed autoSCT, they had received a median of 3.5 prior regimens (up to 13), and 71% had primary refractory disease, all of which underline the marked single-agent activity of BV. The ORR was 75%, with a CR rate of 34% according to the PET-based International Harmonization Project (IHP) criteria. The median PFS was 9.3 months, with a 5-year rate of 22%, but it was much more prolonged (not reached with prolonged follow up) for those patients who achieved CR. Remarkably, PFS rates were not significantly different between CR patients who underwent alloSCT and those who did not. Recently, data on the 5-year study outcomes revealed that the estimated PFS and OS rates were 52% and 64%, respectively, for patients in CR. Interestingly, 9/102 patients in the pivotal trial entered a >5-year disease-free status without additional chemotherapy or alloSCT after achievement of CR with BV post-autoSCT. These results point to the potential curative role of BV in a small minority of patients with rr-cHL postauto-SCT failure.

BV retreatment has also shown significant efficacy, with 60% ORR (30% CR) in patients who had already received BV as salvage therapy, had achieved CR/PR but had withdrawn treatment prior to its completion, and had experienced further disease progression. The median duration of response (DOR) to retreatment was 9.2 months.

A pivotal study suggested that BV was effective after autoSCT failure in patient subgroups defined by disease status (relapsed or refractory), number of prior therapies, age, or disease bulk. However, the exact determinants of response to BV in real life require further evaluation. For example, ORR may be inferior for patients ineligible for autoSCT due to their being chemorefractory, or for those who receive BV after further intervention following autoSCT, who may be more refractory to chemotherapy. These prognostic factors, as well as symptomatic or bulky disease at BV initiation, may be relevant and deserve further consideration.

Real-life data are consistent with the pivotal phase II trial of BV, especially considering that all these studies included not only autoSCT failures but also transplant-naive patients, who may be even more chemorefractory. Interestingly, an Italian observational study of 234 patients confirmed that a small minority of patients (~5%) may achieve durable responses and potential cure with BV only and no additional consolidative therapy.

Although the potential effect of BV on the OS of patients who have failed autoSCT cannot be strictly estimated in the absence of randomized trials, it appears that an OS benefit has probably been achieved. OS rates in the BV era appear better than prior to its introduction, and this persists when only the ‘worst-case scenario’ is taken into account.

**Brentuximab vedotin as a bridge to autoSCT after inadequate response to salvage therapy.** This topic has already been discussed above in the section ‘Bridging autoSCT with novel agents in chemorefractory patients’.

**Brentuximab vedotin as beyond 3rd-line salvage in patients ineligible for autoSCT.** In 2017, Brockelman and colleagues published the combined German and British experience on the use of BV in autoSCT-ineligible patients due to advanced age and comorbidities. A total of 136 patients with
a mean age of 66.7 years received BV following at least 2 lines of therapy (116/136 patients), after being considered ineligible for autoSCT due to comorbidities (74%), age restrictions (57%), patient’s choice (15%), refractoriness to treatment (12%), or mobilization failure (3%). Notably, ECOG PS was ≥2 in 61% of the patients. ORR was almost identical to the pivotal BV trial after autoSCT failure: ORR was 74% and CRs 35%. The median PFS was 15.1 months, without, however, reaching a plateau, while the median OS was 17.8 months. Among 51 deaths, only 33 were attributed to the disease. Thus, BV monotherapy may induce responses of considerable duration in many patients who fall into a highly unfavorable disease category.

**Brentuximab vedotin in special subpopulations.** In case of liver impairment, the dose of BV should be reduced to 1.2 mg/kg every 3 weeks. There are few case reports demonstrating the potential for an uneventful use of BV in patients with severely compromised liver function due to HL, in which jaundice was reversed, although the duration of the benefit was brief. The reversal of jaundice in previously untreated patients with cHL who present with this complication appears also safe and much more successful. In case of severe bone marrow failure, BV may promptly reverse the blood counts, although a more pronounced hematologic toxicity is possible.

**Checkpoint inhibitors as salvage therapy for relapsed/refractory classical Hodgkin lymphoma following brentuximab vedotin failure**

Following both autoSCT and BV failure, the expected outcome of the patients becomes even worse. Only alloSCT could be a viable curative option, but is ultimately applicable only in a minority of patients. Prior to the introduction of checkpoint inhibitors, treatment options were limited to additional chemotherapy regimens or experimental agents with a median PFS of 3.5 months and a short median OS.

Nivolumab and pembrolizumab are well-established checkpoint inhibitors. Nivolumab is a human IgG4, while pembrolizumab is a humanized IgG4 monoclonal antibody, both directed against the PD-1 molecule, which is present on the surface of T-cells. Through the inhibition of the PD-1/PDL-1 pathway, these agents potentiate T-cell activity against the neoplastic cells. Sintilimab and tislelizumab are PD-1 inhibitors developed later in China, and will also be analyzed below.

**Results of major clinical trials of checkpoint inhibitors.** Phase I trials of the checkpoint inhibitors nivolumab and pembrolizumab, the CA209-039 and KEYNOTE-13 studies, were based on 23 and 31 heavily pretreated patients, respectively, and produced impressive results with acceptable toxicity, thus revolutionizing the field of rr-cHL. Patient populations were rather heterogeneous in terms of previous BV and autoSCT treatment. Both studies, published 4.5 and 3 years ago, are already of rather historical significance, since the mid-term results of Checkmate 205 and KEYNOTE-087, the much larger phase II trials of nivolumab and pembrolizumab, respectively, are now available.

Nivolumab was further developed in patients with cHL after autoSCT failure in the four-arm Checkmate 205 trial. Arm D explored the possibility of integrating nivolumab into the AVD regimen as first-line treatment, which is outside the scope of this review. Arms A, B, and C recruited 243 patients with rr-cHL who had failed autoSCT. In all three arms, nivolumab was given at a dose of 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. Later, outside this trial, the approved dose for nivolumab was modified to 240 mg fixed dose every 2 weeks. Arm B (n = 80) was the basis for regulatory approval of nivolumab for the treatment of patients who have failed both autoSCT and BV. Arm A included 63 patients who had failed autoSCT but had not been exposed to BV, while arm C included 100 patients who had failed both ASCT and BV, which could have been given after ASCT (n = 58), prior to ASCT (n = 33), or both (n = 9). The unique feature of arm C was that nivolumab was stopped in patients who entered a sustained CR for 1 year, and could be resumed in case of relapse within 2 years of the last dose. As expected for patients having failed autoSCT, elderly patients (≥60 years old) were very rarely enrolled, representing only 6% of the total study population. Furthermore, enrollment was restricted to patients with ECOG PS 0-1. Interestingly, an early protocol amendment permitted nivolumab to be continued after the occurrence of investigator-assessed disease progression if prespecified criteria were met (see below). Overall, the response rate to nivolumab was 69% with 16%
CRs according to an IRC versus 72% and 33%, when responses were assessed by the investigators. ORRs appeared similar for arms A, B, and C (65%, 68%, and 73%), but the CR rates were better in the less heavily pretreated Arm A (25% versus 13% and 12%, respectively). After a minimum follow-up of 31 months, 20% of the patients were still on treatment. Overall, the median DOR was 18 months, significantly longer in patients with CR as their best response compared with PR (32 versus 13 months). The median PFS per IRC was 15 months, again longer in Arm A (17 months versus 12 and 15, respectively). The median time to next treatment was 29 versus 27 versus 20 months for Arms A, B, and C, respectively. The 2-year OS was excellent at 90%, 86%, and 86%, respectively.

Pembrolizumab was further developed in patients with cHL in the 3-cohort Keynote-087 trial, which had major similarities, but also crucial differences from Checkmate 205. Interestingly, cohort 2 included 81 patients who were considered ineligible for autoSCT but had failed BV. Cohort 1 was identical to Arm B of Checkmate 205, including 69 patients who had failed both autoSCT and BV, while cohort 3 recruited 60 patients with rr-cHL who had failed ASCT, and had not received BV post-autoSCT, although 42% had been exposed to BV prior to transplant. Notably, the dose of pembrolizumab was ~80% lower compared with Keynote-013: the drug was given at the fixed dose of 200 mg every 3 weeks, which is the currently approved scheme, instead of 10 mg/kg every 2 weeks, until disease progression, or intolerable toxicity, or investigator decision, or a maximum of 2 years. Keynote-087 was the basis for the regulatory approval of pembrolizumab for the treatment of patients with rr-cHL in the circumstances described at the end of this section. Similarly to Checkmate 205, elderly patients were very rare, representing only 9% of the total study population (≥65 years old), although the percentage was 18% in cohort 2. Enrollment was again restricted to patients with ECOG PS 0-1. Interestingly, continuation of pembrolizumab beyond the first assessment of disease progression was permitted if the patient was clinically stable, and both the investigator and the sponsor agreed. Overall, the ORR to pembrolizumab was 69%, with 22% CRs according to blinded independent central review (BICR) in the initial report (168); these figures increased to 72% and 28%, respectively, when best responses were taken into account at the 2-year report. Best ORR and CR rates appeared similar for cohorts 1, 2, and 3 [77% (26%), 67% (26%) and 73% (32%), respectively]. In the 2-year report, after a median follow-up of 27.6 months (maximum 32.9), the median PFS was 13.7 months, being shorter in cohort 2 of transplant-ineligible patients (and presumably more chemorefractory). Median PFS was 16.4, 11.1, and 19.4 months for cohorts 1, 2, and 3, respectively. Overall, the median DOR was 16.5 months (22.1, 11.1, 24.4 in cohorts 1, 2, and 3, respectively), being significantly longer in patients with CR as their best response compared with PR (not reached versus 10.9 months). Interestingly, the application of Lugano 2014 response criteria was associated to a higher CR rate compared with Cheson 2007 values. In the most recent update of KEYNOTE-087, the 3-year OS was maintained at exceptionally high levels, reaching 86.4% in the total population (86.3%, 85.7%, 87.6% in cohorts 1, 2, and 3, respectively). Notably, pembrolizumab could be discontinued in patients attaining a CR, provided that they had received at least two doses after the documentation of CR, and had completed ≥6 months of treatment. In this setting, 17 patients received a second course of pembrolizumab (up to 1 year administration, ~17 doses). The ORR to this second course was 68.8% with CR, PR, and SD rates being 31.3%, 37.5%, and 25.0%, respectively, although grade 3–4 treatment-related adverse event (AEs) occurred in 11.9% of patients.

More recently, two other PD-1 inhibitors, sintilimab and tislelizumab, were introduced and tested in Chinese Centers in the phase II trials ORIENT-1 for sintilimab and BGB-A317-203 for tislelizumab, including 92 and 70 patients, respectively. These trials included patients with rr-cHL who had failed at least two prior therapies. Although elderly patients were minimally represented, only 19% of the patients had undergone autoSCT in both trials, because the procedure is not affordable for many patients in China. Furthermore, only 6% had been exposed to BV in the ORIENT-1, and 21% had been exposed to ‘immunotherapy’ in the BGB-A317-203 trial, since BV lacked approval in China. Thus, these patient populations were less heavily pretreated compared with those in...
Checkmate 205 and Keynote-087. The ORR by IRC was 80% (CR 34%) in the ORIENT-1 and 86% (CR 61%) in the BGB-A317-203. At a median follow up of 10.5 months and 7.9 months, respectively, the 6-month PFS was 78% and 80%, which appears numerically similar to that achieved within the Checkmate 205 and Keynote-087 trials in rather worse patient populations. Toxicities were mild, and consistent with those of nivolumab and pembrolizumab (see below). Based on these data, sintilimab was approved in China, and will be tested in the western world. Further details on the Checkmate 205, Keynote-087, ORIENT-1, and BGB-A317-203 trials have been provided elsewhere.\(^\text{178}\)

In conclusion, the Checkmate 205 and Keynote-087 phase II trials confirmed the high response rates, which were almost equally applicable in the prespecified different clinical circumstances of rr-cHL in terms of BV and ASCT pretreatment, as well as the well-tolerated side effects of checkpoint inhibitors. Furthermore, the midterm results confirm that responses can be durable. After appropriate testing, sintilimab and tislelizumab might provide additional options for rr-cHL, raising cost issues, which are becoming increasingly significant.

Currently, the official indication for nivolumab is adult rr-cHL following failure of both autoSCT and BV both in FDA and EMA, although FDA has extended the approval to include patients with rr-cHL who have failed at least 3 lines of therapy, including autoSCT. According to EMA, the official indications for pembrolizumab include the treatment of adult patients with rr-cHL who have either failed both auto-SCT and BV, or have failed at least two regimens and BV, but are ineligible for autoSCT. However, the FDA has granted approval for patients with refractory HL, or who have relapsed after three or more lines of therapy, in both adult and pediatric populations.\(^\text{178}\)

Treatment with checkpoint inhibitors beyond conventionally defined progression. The unique mechanism of action of PD-1 inhibitors may permit the initial growth of the tumor. Immune activation, the basis of the therapeutic action of these drugs, may induce an early ‘inflammatory’ increase of already existing lesions, or the appearance of others that might not have been visible previously. Alternatively, a delayed tumor response may permit an early tumor growth with subsequent reduction, simulating early disease progression.\(^\text{179}\) This should not be misinterpreted as treatment failure, and this is the reason for the development of another set of response criteria specifically designed for lymphomas.\(^\text{179,180}\) However, even after exclusion of such cases of transient tumor flare, several patients may experience disease progression by conventional or PET-based current definitions, but continue to gain clinical benefit from PD-1 inhibitor therapy, even for prolonged time periods. As noted above, an early amendment of the Checkmate 205 permitted nivolumab to be continued after the occurrence of investigator-assessed disease progression if prespecified criteria were met. These criteria included stable PS and perceived clinical benefit per investigator assessment. However, treatment was withdrawn in case of further progression defined by ≥10% further increase in tumor burden. Among 130 patients who developed PD, 80 (62%) were treated beyond progression (TBP) and 50 were not. The 2-year OS rate for those TBP was 87%, and was significantly better than OS in patients not eligible to be TBP. Interestingly, at the last report, the 3-year OS of Checkmate 205 patients who achieved a CR was clearly >90%, while it was ~80% for both patients with PR and SD as best response, despite their clearly different PFS. However, even the minority of patients (11%) who had PD as best response had a 3-year OS of 50% or more.\(^\text{171}\) These data suggest that checkpoint inhibitors exert a prolonged beneficial effect on the disease, which is not solely determined by the depth of response, and highlight the importance of TBP, as long as a clinical benefit is being obtained. Whether the ‘10% further progression’ stopping rule should be applied in clinical practice as done in Checkmate 205, is not clear and should be evaluated in clinical trials and real-life studies.

Modulation of the efficacy of checkpoint blockade and potential effect of checkpoint inhibitors on subsequent chemotherapy. In the era of novel agents, one of the main concerns in modern therapeutic approach of rr-cHL remains the treatment of patients that fail checkpoint blockade therapy. In the earliest phase of clinical introduction of checkpoint inhibitors in ‘real-world’ practice, Falchi and colleagues suggested the potential favorable role of hypomethylating agent 5-azacitidine on checkpoint blockade response through a
synergistic priming effect on the immune system.¹⁸¹ Later, in a phase II study of 86 rr-cHL patients who had received at least two lines of previous therapy, the addition of low-dose decitabine to the checkpoint inhibitor camrelizumab led to higher CR rates in anti-PD1-naïve patients that reached 71% versus 32% in the anti-PD1 monotherapy arm. The study revealed the potential of the combination to induce responses in patients who had been previously refractory to PD1 inhibition.¹⁸²

Besides evidence supporting the optimization of tumor response to PD1-blockade with the addition of hypomethylating agents, a retrospective trial of 30 patients with rr-cHL and unsatisfactory response to anti-PD1 therapy proposed the beneficial effect of previous checkpoint blockade on the following chemotherapy administration, either alone or in combination with the previous anti-PD1 agent, by demonstrating 61% and 90% objective response rates in the ‘sequential’ and ‘combination’ strategy, respectively.¹⁸³ Recently, Carreau and colleagues evaluated 77 heavily pretreated cHL patients who received a subsequent line of therapy after anti-PD1 blockade. Although, ORR to post-anti-PD1 agent correlated with the previous PD-1 blockade response, ORR of nonresponders to anti-PD1 treatment (SD and PD) was 37%, without statistical difference in survival based upon treatment choice, implicating that a small, but significant, proportion of unfavorable patients who had failed on PD-1 blockade, may be sensitized to subsequent therapy and proceed to SCT.¹⁸⁴ However, further prospective studies are required to shed light on this attractive hypothesis.

Toxicities of checkpoint inhibitors. The nature of adverse reactions induced by checkpoint inhibitors differs from traditional cytotoxic therapy, and is due mainly to T-cell hyperactivation. In Checkmate 205 and Keynote-087, drug-related AEs, which occurred in ≥10% of the patients, included skin rash and fatigue in both studies, plus diarrhea, pruritus, nausea, and infusion-related reactions with nivolumab, and hypothyroidism and pyrexia with pembrolizumab. These AEs are mild and easily manageable. Grade 3/4 drug-related AEs were rare; those occurring in ≥2% of the patients included neutropenia in both studies and elevations in lipase, amylase, and transaminases in Checkmate 205. Similar grade 4 events were observed at lower frequency with pembrolizumab. In updated reports of both studies, approximately 7% of the patients had discontinued treatment due to drug-related AEs. Among them, pneumonitis (2%) and autoimmune hepatitis (1%) were notable in Checkmate 205, while pneumonitis (3%) and infusion-related reactions were recorded in the Keynote-087 study. However, myocarditis, myelitis, myositis, epilepsy, organizing pneumonia, cytokine release syndrome, etc., were the cause of treatment discontinuation in isolated cases. Interestingly, all deaths recorded in these studies were unrelated to the study drugs.

It should be stressed that immune-related adverse AEs (IMAEs) are the most notable form of toxicity of checkpoint inhibitors, including some of the above mentioned events, as well as others occurring even more rarely. Thus, hypothyroidism and thyroiditis, or, rarely, hyperthyroidism, rash, hepatitis, pneumonitis, colitis, diabetes, hypophysitis, adrenal insufficiency, autoimmune nephritis, etc., should be kept in mind and excluded in cases of clinical suspicion or even carefully monitored over time. The median time to occurrence of IMAEs is ~12 weeks (range between 1 and 112 weeks). Specific guidelines for the management of the IMAEs associated with checkpoint inhibitors have been published elsewhere¹⁸⁵,¹⁸⁶

In addition, pseudoprogression, an immune-mediated tumor flare, may be observed early during checkpoint inhibitor therapy, and may provoke treatment discontinuation. For this purpose, modified criteria of response have been developed in order to account for this and avoid inappropriate premature drug discontinuation, as discussed above.¹⁷⁹ Finally, PD-1 inhibition in patients who have relapsed after alloSCT may be complicated with relatively high rates of GVHD, though being highly efficient.¹⁸⁷,¹⁸⁸

Other promising novel agents for relapsed/refractory classical Hodgkin lymphoma

Several novel agents had shown promising results, but their development was delayed or stopped with the appearance of the impressive results obtained with BV and checkpoint inhibitors. The potential role of such targeted agents in rr-cHL, including mTOR inhibitors, lenalidomide, histone deacetylase inhibitors (HDACi), and JAK inhibitors, as well as inhibitors of the B-cell
receptor (BCR) pathway\textsuperscript{189,210} and details of major clinical trials of these agents are summarized in Table 3.

**Everolimus** is an oral inhibitor of the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling pathway. Following the encouraging results of an initial phase II study on 19 patients,\textsuperscript{189} everolimus 10 mg daily p.o. was evaluated in a phase II study of 57 evaluable, heavily pretreated rrHL patients (details in Table 3).\textsuperscript{190} The ORR was 46\% with 9\% CRs, the disease control rate 81\%, the median time to response was 57 days, and the median PFS 7.3 months. Seven patients were long-term responders (12 months or longer), including five in PR. Notably, one PR patient has been on everolimus for 4.7 years.\textsuperscript{190} Similar results were reported in a retrospective analysis of 33 heavily pretreated rr-cHL patients from Brazil.\textsuperscript{191} The major toxicities of the drug include thrombocytopenia, anemia, fatigue, rash, and stomatitis,\textsuperscript{190} while pneumonitis can be an issue in a minority of patients, being grade 3/4 very rarely.\textsuperscript{191} Despite the single agent activity of everolimus, the combination everolimus-DHAP did not prove successful in the HD-R3i trial.\textsuperscript{192}

**Lenalidomide** is an agent exerting immunomodulatory activity mainly through direct induction of apoptosis, antiangiogenesis, and activation of T-cell mediated immune response. Two small clinical trials demonstrated the efficacy of lenalidomide in heavily pretreated rr-cHL.\textsuperscript{193} Later, in a multicenter study of 38 patients, the ORR was 17\% with one CR.\textsuperscript{193} Recently, the efficacy of lenalidomide-bendamustine combination was evaluated in a phase I/II study, with 75\% ORR and 44\% CRs independently of previous autoSCT.\textsuperscript{200}

Panobinostat, Vorinostat, Mocetinostat, and Entinostat regulate several oncogenic pathways by inhibiting histone deacetylase (HDAC). Panobinostat (40 mg t.i.w. in 21-day cycles) was evaluated in a large pivotal international phase II study of 129 rr patients after autoSCT, with ORR of 27\% and SD rates of 55\%. The median DOR and PFS were 6.9 and 6.1 months, respectively. The most common grade 3/4 toxicities were, by far, thrombocytopenia, followed by anemia and neutropenia.\textsuperscript{194} Few studies have examined the combination of panobinostat with either everolimus, with a synergistic effect in HL cell lines,\textsuperscript{201} or with lenalidomide in rr-HL patients with no additional favorable outcome compared with the single agents.\textsuperscript{202,203} Vorinostat had limited efficacy in a phase II study of 27 patients.\textsuperscript{204} Lastly, Younes and colleagues evaluated the efficacy and tolerability of *mocetinostat* in an open-label, single-arm, phase II study in 51 patients with rr-HL, 28 of which received the finally recommended dose of 85 mg p.o. t.i.w. and achieved an ORR of 26\%. The 110 mg dose level provided slightly better ORR, but was not well tolerated, with two deaths potentially related to treatment, while the results of entinostat and resminostat were less encouraging.\textsuperscript{195–197}

JAK inhibitors could be active in HL through the blockade of the JAK-STAT pathway. Unfortunately, the clinical results of pacritinib and ruxolitinib were heterogeneous and rather disappointing (Table 3).\textsuperscript{198,205,206} A further study of ruxolitinib is ongoing (NCT02164500).\textsuperscript{207}

Targeting the B-cell receptor (BCR) pathway with ibrutinib, an oral Bruton’s kinase inhibitor, has shown some efficacy in a limited number of patients.\textsuperscript{208,209} Ibrutinib is also being evaluated in combination with BV (NCT02744612) and nivolumab (NCT02940301).\textsuperscript{210} Similarly, idelalisib, a selective PI3K\(\delta\) inhibitor, might be active in HL, exerting its effects both on the HRS and T-cells. It has shown modest activity in 25 patients heavily pretreated with rr-cHL (Table 3). The median DOR for the five responders was 8.4 months. Rash, diarrhea, and pneumonitis (4\%) were AEs of special interest.\textsuperscript{199}

The potential role of chimeric antigen receptor-modified T cell (CAR-T) therapy in HL is currently under development, while the clinical benefit from the use of such strategies remains obscure. In cHL, the main molecular targets are CD30 and CD123 proteins or EBV-related proteins. Ramos and colleagues reported the administration of CD30\textsuperscript{+} CAR-T in seven patients with HL.\textsuperscript{211} Similarly, Bollard and colleagues reported the infusion of autologous T-cells against EBV antigens latent membrane protein 1 and 2 (LMP1 and LMP2) in 50 patients with EBV-associated lymphoma, including 25 HL patients: when administered in patients with active, relapsed disease, the ORR was \(\approx 50\%), while all high-risk patients who received these products as consolidation therapy remained in remission.\textsuperscript{212}
| Parameter                                           | Everolimus\(^{190}\) | Lenalidomide\(^{193}\) | Panobinostat\(^{194}\) | Mocetinostat\(^{195}\) | Entinostat\(^{196}\) | Resminostat\(^{197}\) | Ruxolitinib\(^{198}\) | Idealisib\(^{199}\) |
|----------------------------------------------------|----------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Dosage                                             | 10 mg/day p.o.       | 25 mg/day p.o., day 1–21/28 days | 40 mg p.o., t.i.w. continuously | 85 mg p.o. t.i.w. | 10 or 15 mg /2weeks or 15 mg/week ×3weeks/28 days | 600–800 mg ×5days/14 days | 20 mg b.i.d. p.o. continuously | 150 mg b.i.d. continuously |
| Patients [n]                                       | 57                   | 38                     | 129                    | 28                     | 49                     | 37                     | 33                     | 25                     |
| Age [median (range) years]                         | 32 [19–77]           | 34 [25–62]             | 32 [18–75]             | 34 [19–68]             | 33 [19–73]             | 34 [19–71]             | 37 [19–80]             | 42 [21–80]             |
| ECOG PS 0–1 (%)                                    | 97                   | 92                     | NR                     | 100                    | 100                    | 94                     | 79                     | 95                     |
| Prior ASCT (%)                                     | 67                   | 87                     | 100                    | 82                     | 80                     | 57                     | 70                     | 72                     |
| Prior regimens [median (range) n]                  | 4 [1–17]             | 4 [2–9]                | 4 [2–7]                | 5 [1–9]                | 3 [1–10]               | 6 [2–14]               | 5 [1–16]               | 5 [2–9]                |
| Time from diagnosis to last relapse/progression [median (range) mos] | 39 [7–221]           | NR                     | NR                     | NR                     | NR                     | NR                     | 55 [19–216]            |
| ORR (%)                                            | 46                   | 19                     | 27\(^{a}\)             | 26                     | 12                     | 34\(^{e}\)             | 19                     | 20                     |
| CRR (%)                                            | 9                    | 3                      | 4\(^{e}\)              | 0                      | 0                      | 3                      | 0                      | 4                      |
| DCR (%)                                            | 81                   | 33\(^{a}\)             | 82                     | 69\(^{c}\)             | 51\(^{d}\)             | 37\(^{e}\)             | 53                     | 48                     |
| DOR [median, mos]                                  | 6.0                  | 6.7                    | 8.2                    | 6.9\(^{c}\)            | 5.1\(^{d}\)            | 3.7\(^{e}\)            | 7.7                    | 8.4                    |
| PFS [median, mos]                                  | 7.3                  | 4.0                    | 6.1                    | −9.0                   | 5.5                    | 2.3                    | 3.5                    | 2.3                    |
| Median duration of drug exposure [months, range]   | 4.1 [1 day–4.7 years] | 4 cycles [1–43+]       | 4.3 [<1–20.2]          | NR                     | 1.4 [0.2–8.0]          | 4 [1–22]               | 3.6 [0.5–25.2]         |
| Prolonged drug administration [n, %]               | 7 [12%] for ≥1 year  | 7 [19%] for ≥1 year    | 3 [3%] for ≥1 year     | NR                     | 3 [6%] for ≥1 year     | NR, but ↓↓             | 4 [12%] for ≥1 year    |

Generally, prior exposure to BV in these trials was minimal or absent, except for 82% in the ruxolitinib and 92% in the idealisib trial. ASCT, autologous stem-cell transplantation; BV, brentuximab vedotin; CRR, complete response rate; DCR, disease control rate; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; NR, not reported; ORR, overall response rates; PFS, progression-free survival.

\(^{a}\)Including SD for 6 months or more.
\(^{b}\)By CT/MRI [no PET].
\(^{c}\)Only 30% if only durable SD included.
\(^{d}\)Only 24% if only durable SD included.
\(^{e}\)Including 23% partial metabolic responses with SD.
Further details on CAR-T cells and other forms of immunotherapy as discussed in more detail elsewhere.178

The role of allogeneic stem-cell transplantation in the era of novel agents

Being, in the past, the only strategy with curative potential in rr-cHL, the role and the optimal timing of alloSCT have been questioned in the era of BV, and, especially, PD-1 inhibitors. Although patients who fail autoSCT now have improved outcomes, and a small minority may even be cured with novel agents, they still represent an unmet medical need.130,131 The existence of graft versus HL effect is suggested by the association of chronic GvHD (cGvHD) with lower relapse rates, and this forms the rationale of alloSCT in HL.213,214

Historically, the applicability of alloSCT can be divided in three time periods. During the first period, up to 2000, the use of myeloablative conditioning (MAC) was the rule, with disappointing OS of 20–30%, owing mainly to unacceptable nonrelapse mortality (NRM) of 30–50%.213,215–218 During the second period, 2000–2010, the use of reduced intensity conditioning (RIC) dominated, leading to substantially lower NRM rates of 15–30%,147,148,213,219–222 lower incidence of acute graft versus host disease (aGvHD) with similar chronic GvHD (cGvHD), and, consequently, an OS still in favor of RIC.214 The superiority of RIC alloSCT over conventional chemotherapy after autoSCT failure was suggested by a large, Italian, donor versus no donor retrospective study,214 demonstrating PFS rates between 30% and 40%, and RIC had, therefore, been established as the standard therapeutic strategy for patients who progress after autoSCT.214,223–225 Despite the improvement in the outcomes of alloSCT for rr-cHL during this second period, as recently shown in a meta-analysis including 42 trials,224 no plateau in the survival curves was evident, implying that there was still room for improvement.224

The most important prognostic factor for a favorable outcome of alloSCT remains chemosensitive disease, although a small fraction of chemoresistant patients may be cured.147,214,223,225,226 However, consecutive chemotherapy regimens to induce remission frequently impair patients’ PS, rendering them ineligible for alloSCT. In this perspective, novel agents may induce a ‘low burden’ state without significant PS decline in previously ‘chemoresistant’ patients, turning them into ideal candidates for alloSCT. Nevertheless, by changing the natural history of rr-cHL from a fatal to a ‘chronic’ disease, novel agents pose a great dilemma on whether, and when, patients should be referred for alloSCT.

Given that <10% of all patients who receive BV for rr-cHL after autoSCT can achieve long-term disease control without further treatment,124,152 it was thought reasonable to consolidate patients with PR/SD to BV with alloSCT as soon as possible,227 taking into consideration that pre-alloSCT BV does not negatively affect the outcome of transplantation.228 Furthermore, due to the evolving position of BV in the treatment algorithm of HL, we will encounter patients who will have already received BV earlier in disease course. Thus, after autoSCT failure, BV will not be an option for many patients, especially those who progress after autoSCT consolidation.

The introduction of PD-1 inhibitors has produced even more uncertainty on whether, and which, patients should be referred for an alloSCT, and when, as both nivolumab and pembrolizumab induce rapid, impressive, and durable responses in approximately 70% of patients who have failed multiple treatments, including autoSCT and BV, albeit with low CR rates.166,168 Patients progressing on BV should be treated with PD-1 inhibitors, given the dismal results with alloSCT in chemoresistant cases. Whether patients who achieve PR/SD with BV should be treated with PD-1 inhibitors in an effort to deepen responses before alloSCT is a matter of debate. A few facts have to be considered; firstly, the achievement of metabolic CR is not necessarily associated with significantly better SCT outcomes; that is, a positive PET/CT should not preclude alloSCT, while increasing lines of treatment prior to the procedure correlate with NRM.229 Secondly, there is some evidence, although as yet immature, that PD-1 inhibitors before alloSCT may be associated
with more frequent liver veno-occlusive disease, severe (grade IV) GvHD, and a noninfectious febrile syndrome responding to steroids.\textsuperscript{230,231} Taking these facts into consideration, patients with a PR, or even SD, and a low disease burden after BV, should be at least referred for alloSCT consultation. Recent evidence suggests that, despite the moderate risk of alloSCT complications after PD-1 blockade, the long-term efficacy of alloSCT may be actually enhanced by prior exposure to these agents. However, a close collaboration between the treating physicians and the transplant center is mandatory in decision making and transplant preparation.

Although the follow up of PD-1 inhibitors’ studies is still short, there is compelling evidence that even nonresponders or progressors according to conventional criteria derive long-term benefit from TBP, and may not need next antilymphoma treatment for protracted periods of time, rendering rr-cHL a chronic disease. It would be desirable for these new ‘immunologic’ drugs to alleviate the need for an alloSCT; however, the field is still evolving. Given the complexity of patient and timing selection, specific recommendations on the application of PD-1 inhibitors in the context of alloSCT have been published recently: experts in the field recommend to keep responders on PD-1 inhibitors rather than stopping treatment and proceeding to alloSCT, whereas heavily pretreated patients due to multiply refractory disease are the ones who should be considered for an early alloSCT, after response to PD-1 treatment.\textsuperscript{232} For patients scheduled for alloSCT, a 6-week PD-1 treatment-free period is recommended before the procedure. Other considerations include the use of bone marrow grafts instead of peripheral blood, the use of PtCy for GvHD prevention, and prompt implementation of GvHD treatment.\textsuperscript{232}

On the other hand, the immune effects of PD-1 inhibitors are even more detrimental when given after alloSCT. Although responses are impressive and durable in this setting as well, GvHD has been reported in 30–55% of patients, most frequently acute. PD-1-induced aGvHD occurs after the initial one to two infusions, and is frequently severe and steroid-refractory.\textsuperscript{187,188} The probability of acute GvHD is higher, the closer to alloSCT the PD-1 inhibitor is given, and in patients with a previous history of aGvHD,\textsuperscript{187} although PD-1-induced aGvHD was observed also in patients with no prior history of aGvHD.\textsuperscript{188} Previous post-Cy or antithymocyte globulin GVHD prophylaxis may be associated with less aGvHD, with PD-1 blockade after alloSCT. Further recommendations include avoiding PD-1 inhibitors during the first 6 months after alloSCT, and initiating treatment at lower doses (e.g. 0.5 mg/kg nivolumab).\textsuperscript{232}

Another recent evolution is the reconsideration of the conditioning regimens and type of transplants. The most intriguing progress has been made in haploidentical transplantation with PtCy, providing a donor in a timely manner for the majority of rr-cHL patients, while PtCy as GvHD prophylaxis is associated with less immune complications in the era of PD-1 inhibitors, before or after alloSCT, without alleviating graft versus lymphoma effect. Results are impressive, with PFS and OS rates of 51–63% and 63–77%, respectively, with acceptable NRM (4–31%).\textsuperscript{233–235} In the haploidentical alloSCT setting, disease status pretransplantation is of prognostic importance, with SD patients having a dismal prognosis. The use of peripheral blood stem-cells as graft source is associated with better long-term outcomes due to lower relapse rates.\textsuperscript{233} However, excessive complications may be encountered with PBSC in the context of previous PD-1 treatment, as stated above.

As the role of alloSCT is changing in the era of novel agents, its exact position in rr-cHL is not yet clearly defined. PD-1 inhibitors may actually not undermine its role, but establish alloSCT as another tool after PD-1 failure, especially in the haploidentical PtCy setting.

### Conclusion

The outcome of patients with rr-cHL has improved considerably in recent years owing to the approval of highly active novel agents in the form of brentuximab vedotin and PD-1 inhibitors. Although no randomized trials have been conducted to provide formal proof, it is almost undisputable that the OS of these patients has been prolonged, since, in most of them, a rapidly lethal disease can be transformed in a chronic, smoldering, disease. As autoSCT remains the standard of care for second-line therapy for most patients with rr-cHL, optimization of second-line
regimens with the use of brentuximab vedotin, or, in the future, checkpoint inhibitors, is promising to increase both the eligibility rate for transplant and the final outcome. The need for subsequent therapy, and especially alloSCT, can be reduced with brentuximab vedotin consolidation for 1 year, while pembrolizumab is also tested in this setting. Several other drug categories appear to be active in rr-cHL but their development has been retarded by the appearance of brentuximab vedotin, nivolumab, and pembrolizumab, which have dominated the field of rr-cHL treatment during the last 5 years. Combinations of active drugs in chemo-free approaches and modulation of PD-1 inhibitors’ activity by hypomethylating agents may further increase efficacy, and hopefully reduce toxicity in rr-cHL, but are still under development.

**Funding**
The author(s) received no financial support for the research, authorship, and publication of this article.

**Conflict of interest statement**
TPV has been an advisory board member and has received honoraria from TAKEDA, BMS and MSD. MKA has been an advisory board member and has received honoraria from TAKEDA and BMS.

**ORCID ID**
Theodoros P. Vassilakopoulos [https://orcid.org/0000-0001-8766-1853](https://orcid.org/0000-0001-8766-1853)

**References**

1. Engert A, Eichenauer DA, André M, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29(Suppl. 4): iv19–iv29.

2. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Hodgkin lymphoma. 2019, https://seer.cancer.gov/statfacts/html/hodg.html.

3. Cancer Research UK. Hodgkin lymphoma incidence statistics UK 2019, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/hodgkin-lymphoma/incidence#heading-One.

4. International Agency for Research on Cancer. Hodgkin lymphomas. In: Swerdlow SHC, Harris E, Jaffe NL, et al. (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Vol 2. Lyon: International Agency for Research on Cancer, 2017, pp. 423–442.

5. Mathias S, Hartmann S and Kuppers R. Hodgkin lymphoma: pathology and biology. *Semin Hematol* 2016; 53: 139–147.

6. Vassilakopoulos TP and Angelopoulou MK. Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years. *Semin Hematol* 2013; 50: 4–14.

7. Camellos GP, Rosenberg SA, Friedberg JW, et al. Treatment of Hodgkin lymphoma: a 50-year perspective. *J Clin Oncol* 2014; 32: 163–168.

8. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. *N Engl J Med* 2010; 363: 640–652.

9. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. *N Engl J Med* 2015; 372: 1598–1607.

10. Sasse S, Brockelmann PJ, Goergen H, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials. *J Clin Oncol* 2017; 35: 1999–2007.

11. Engert A and Raemaekers J. Treatment of early-stage Hodgkin lymphoma. *Semin Hematol* 2016; 53: 165–170.

12. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD11 trial. *J Clin Oncol* 2010; 28: 4199–4206.

13. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD14 trial. *J Clin Oncol* 2012; 30: 907–913.

14. Ferme C, Thomas J, Brice P, et al. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: results of the European organisation for research and treatment of cancer (EORTC)-Groupe d’Etude des Lymphomes de l’Adulte (GELA) H9-U intergroup randomised trial. *Eur J Cancer* 2017; 81: 45–55.

15. Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-
adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol* 2017; 35: 1786–1794.

16. Fuchs M, Goergen H, Kobe C, et al. PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the German Hodgkin study group. *Blood* 2018; 132(Suppl. 1): 925.

17. Barrington SF, Phillips EH, Counsell N, et al. Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID study. *J Clin Oncol* 2019; 37: 1732–1741.

18. Villa D, Sehn LH, Aquino-Parsons C, et al. Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. *Haematologica* 2018; 103: e590–e593.

19. Cottereau ASV, Loft A, Casasnovas A, et al. Deauville score evaluation of PET2 positive patients included in the H10 trial. Paper presented at 7th International Workshop on PET in lymphoma and myeloma, 4–6 October 2018, Menton, France, p. 59.

20. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. *J Clin Oncol* 2003; 21: 607–614.

21. Vassilakopoulos TP, Angelopoulos MK, Siakantaris MP, et al. Prognostic factors in advanced stage Hodgkin’s lymphoma: the significance of the number of involved anatomic sites. *Eur J Haematol* 2001; 67: 279–288.

22. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V Regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: United Kingdom national cancer research institute lymphoma group study ISRCTN 64141244. *J Clin Oncol* 2009; 27: 5390–5396.

23. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern cooperative oncology group (E2496). *J Clin Oncol* 2013; 31: 684–691.

24. Vassilakopoulos TP and Johnson PW. Treatment of advanced-stage Hodgkin lymphoma. *Semin Hematol* 2016; 53: 171–179.

25. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. *N Engl J Med* 2011; 365: 203–212.

26. Chisési T, Bellei M, Luminari S, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study from the Intergruppo Italiano Linfomi. *J Clin Oncol* 2011; 29: 4227–4233.

27. Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. *J Clin Oncol* 2016; 34: 1175–1181.

28. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. *J Clin Oncol* 2009; 27: 4548–4554.

29. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. *Lancet Oncol* 2013; 14: 943–952.

30. Engert A. Hodgkin’s lymphoma: who needs consolidation treatment? *Lancet* 2015; 385: 1810–1812.

31. Engert A, Goergen H, Markova J, et al. Reduced-intensity chemotherapy in patients with advanced-stage Hodgkin lymphoma: updated results of the open-label, international, randomised phase 3 HD15 trial by the German Hodgkin study group. *HemaSphere* 2017; 1: e5.

32. Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. *N Engl J Med* 2016; 374: 2419–2429.

33. Press OW, Li H, Schoder H, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest oncology group S0816. *J Clin Oncol* 2016; 34: 2020–2027.

34. Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles:
long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol 2018; 36: 454–462.

35. Agostinelli C, Gallamini A, Stracqualursi L, et al. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin’s lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematol 2016; 3: e467–e479.

36. Stephens DM, Li H, Schöder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach for stage III/IV Hodgkin lymphoma. Blood 2019; 134: 1238–1246.

37. Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin study group. Lancet Oncol 2017; 18: 454–463.

38. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group. Lancet 2018; 390: 2790–2802.

39. Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019; 20: 202–215.

40. Connors JM, Jurczak W, Strauss DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 2018; 378: 331–344.

41. Gallamini A, Straus D, Dlugosz-Danecka M, et al. Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: 3-year update of the Echelon-1 study. S820. HemaSphere 2019; 3: 362–363.

42. Hutchings MR, Gallamini J, Illes A, et al. Brentuximab vedotin plus chemotherapy in patients with high-risk advanced-stage classical Hodgkin lymphoma (CHL): results of prespecified sub-group analyses from echelon-1. Presented at 11th International Symposium on Hodgkin Lymphoma, Cologne, Germany: HemaSphere, 2018, p. 34.

43. European Medical Agency. Adcetris. Product information: Takeda Pharma A/S, Denmark, 2019, https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf.

44. Eichenauer DA, Plutschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin study group. Lancet Oncol 2017; 18: 1680–1687.

45. Vassilakopoulos TP and Böll B. Treatment of Hodgkin lymphoma – new and developing therapies and their potential role in standard of care. European Oncology & Haematology 2019; 15(1): 53–63. 10.17925/EOH.2019.15.1.53.

46. Brockelmann PJ, Goergen H, Kohnhorst C, et al. Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin study group HD7 to HD12 trials. J Clin Oncol 2017; 35: 1444–1450.

47. Vassilakopoulos TP, Siakantaris MK, Kokoris MP, et al. Very late relapses in patients with Hodgkin’s lymphoma. Haematologica 2005; 90(Suppl. 2): 72.

48. Vassilakopoulos TP, Kravariti MK, Dimopoulou E, et al. Very late relapses (VLRS) in Hodgkin lymphoma (HL) occurring ≥ 5 years after initial treatment with chemotherapy ± radiotherapy (CT ± RT): pattern of risk over 35 years and the significance of histology. Presented at 11th International Symposium on Hodgkin Lymphoma, 27–29 October, Cologne, Germany: HemaSphere, 2018, p. 26.

49. Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin lymphoma study group. J Clin Oncol 2005; 23: 1522–1529.

50. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Hodgkin’s lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy. Eur J Haematol 2002; 68: 289–298.

51. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359: 2065–2071.

52. Vassilakopoulos TP, Liaskas A, Rizzuto G, et al. Treatment strategies and prognostic factors for the outcome of very late relapses (VLRS) occurring ≥ 5 years after initial treatment with chemotherapy ± radiotherapy (CT ± RT) in Hodgkin lymphoma (HL): a joint study from the University of Athens and istituto nazionale
53. Boll B, Goergen H, Arndt N, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin study group. *J Clin Oncol* 2013; 31: 4431–4437.

54. Vassilakopoulos TP, Boutsikas G, Kokoris SI, et al. Clinical and laboratory features, outcome after anthracycline-based treatment and comparison with younger patients: a single center experience. *Haematologica* 2011; 96(Suppl. 2): 1–678.

55. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. *Lancet* 1993; 341: 1051–1054.

56. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2015; 385: 1853–1862.

57. Moskowitz C, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. *Blood* 2018; 132: 2639–2642.

58. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. *Haematologica* 2007; 92: 35–41.

59. Aparicio J, Segura A, Garcia S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. *Ann Oncol* 1999; 10: 593–595.

60. Labrador J, Cabrero-Calvo M, Perez-Lopez E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma. *Ann Hematol* 2014; 93: 1745–1753.

61. Martinez C, Diaz-Lopez A, Rodriguez-Calvillo M, et al. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. *Br J Haematol* 2016; 174: 859–867.

62. Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. *J Clin Oncol* 2010; 28: 5074–5080.

63. Tsirkinidis PV, Moschoyiannis TP, Galanis M, et al. ESHAP vs GIN as salvage and mobilizing regimens in relapsed or refractory Hodgkin lymphoma (HL). *Haematologica* 2007; 92(Suppl 5): 79.

64. Rodriguez J, Rodriguez MA, Fayad L, et al. ASHAP: a regimen for cyto reduction of refractory or recurrent Hodgkin’s disease. *Blood* 1999; 93: 3632–3636.

65. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. *Blood* 2001; 97: 616–623.

66. Sibon D, Ertault M, Al Nawakil C, et al. Combined ifosfamide, etoposide and oxaliplatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. *Br J Haematol* 2011; 153: 191–198.

67. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National cancer institute of Canada clinical trials group. *Ann Oncol* 2003; 14: 1762–1767.

68. Chau I, Harries M, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin’s and non-Hodgkin’s lymphoma. *Br J Haematol* 2003; 120: 970–977.

69. Moskowitz AJ, Hamlin PA, Gerecitano J, et al. Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem-cell transplant. *Blood* 2009; 114: 720.

70. Hertzberg MS, Crombie C, Benson W, et al. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin’s lymphoma and Hodgkin’s disease. *Ann Oncol* 2003; 14( Suppl. 1): i11–i16.

71. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. *Ann Oncol* 2002; 13: 1628–1635.

72. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and
pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. *Ann Oncol* 2007; 18: 1071–1079.

73. Sasse S, Alram M, Muller H, *et al.* Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-study group. *Leuk Lymphoma* 2016; 57: 1067–1073.

74. Shah GL, Yahalom J, Matasar MJ, *et al.* Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem-cell transplantation. *Br J Haematol* 2016; 175: 440–447.

75. Adams HJ and Kwee TC. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem-cell transplantation: systematic review and meta-analysis. *Ann Hematol* 2016; 95: 695–706.

76. Balzarotti M, Brusamolino E, Angelucci E, *et al.* B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). *Leuk Lymphoma* 2016; 57: 2375–2381.

77. Moskowitz AJ, Schoder H, Gavane S, *et al.* Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. *Blood* 2017; 130: 2196–2203.

78. Gallamini A. Relapsed/refractory HL: FDG-PET is the trump card. *Blood* 2017; 130: 2154–2155.

79. Moskowitz CH, Matasar MJ, Zelenetz AD, *et al.* Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. *Blood* 2012; 119: 1665–1670.

80. Jabbour E, Hosing C, Ayers G, *et al.* Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. *Cancer* 2007; 109: 2481–2489.

81. Moskowitz AJ, Yahalom J, Kewalramani T, *et al.* Pretransplantation functional imaging predicts outcome following autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. *Blood* 2010; 116: 4934–4937.

82. Smeltzer JP, Cashen AF, Zhang Q, *et al.* Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem-cell transplantation. *Biol Blood Marrow Transplant* 2011; 17: 1646–1652.

83. Devillier R, Coso D, Castagna L, *et al.* Positron emission tomography response at the time of autologous stem-cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. *Haematologica* 2012; 97: 1073–1079.

84. Akhtar S, Al-Sugair AS, Abouzied M, *et al.* Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT. *Bone Marrow Transplant* 2013; 48: 1530–1536.

85. Angelopoulou MK, Rondogianni M, Pappis P, *et al.* The prognostic significance of PET scan before and after high dose therapy and autologous stem-cell transplantation (ASCT) in relapsed/refractory Hodgkin lymphoma (HL) patients. *Haematologica* 2012; 97(Suppl 1): 178–179.

86. Brockelmann PJ, Angelopoulou MK and Vassilakopoulos TP. Prognostic factors in Hodgkin lymphoma. *Semin Hematol* 2016; 53: 155–164.

87. Brockelmann PJ, Muller H, Casasnovas O, *et al.* Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. *Ann Oncol* 2017; 28: 1352–1358.

88. Ghesquieres H, Stamatoullas A, Casasnovas O, *et al.* Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. *Leuk Lymphoma* 2013; 54: 2399–2404.

89. Moskowitz AJ, Hamlin PA Jr, Perales MA, *et al.* Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. *J Clin Oncol* 2013; 31: 456–460.

90. Corazzelli G, Angrilli F, D’Arco A, *et al.* Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. *Br J Haematol* 2013; 160: 207–215.

91. El Cheikh J, Massoud R, Haffar B, *et al.* Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral transplantation.
Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin. Br J Haematol 2017; 179: 841–843.

Zinzani PL, Vitolo U, Viviani S, et al. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma: experience with 27 patients. Clin Lymphoma Myeloma Leuk 2015; 15: 404–408.

Santoro A, Mazza R, Pulsoni A, et al. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol 2016; 34: 3293–3299.

Gutierrez A, Rodriguez J, Martinez-Serra J, et al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Onco Targets Ther 2014; 7: 2093–2100.

Ozdemir E, Aslan A, Turker A, et al. Gemcitabine in combination with oxaliplatin (GEMOX) as a salvage regimen in patients with relapsed/refractory Hodgkin’s lymphoma. Blood 2015; 126: 1517.

Hu B, Younes A, ClarLat L, et al. The final report of a phase I/II study of panobinostat in combination with ICE (ifosfamide, carboplatin and etoposide) in patients (pts) with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). Blood 2016; 128: 1833.

Karuturi M, Younes A, Fayad L, et al. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. Leuk Lymphoma 2016; 57: 445–447.

Moskowitz AJ, Schoder H, Yalahom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015; 16: 284–292.

Moskowitz AJ, Yahlom H, McCall J, et al. PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma—lack of improvement with 3 versus 2 cycles of weekly brentuximab vedotin. Haematologica 2016; 101(Suppl. 5): abstract P088.

Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II Trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2015; 21: 2136–2140.

Herrera A, Martin J, Armenian P, et al. Post transplant outcomes in a multicenter phase II study of brentuximab vedotin as first line salvage therapy in relapsed or refractory Hodgkin lymphoma prior to autologous stem-cell transplantation. Haematologica 2016; 101(Suppl. 5): abstract P086.

Herrera AF, Palmer J, Martin P, et al. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 2018; 29: 724–730.

Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol 2019; 30: 612–620.

Hagenbeek A, Zijlstra JM, Plattel WJ, et al. Combining brentuximab vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin lymphoma: the phase II HOVON/LLPC transplant BRaVE study. Blood 2018; 132(Suppl. 1): 2923.

Cassaday RD, Fromm J, Cowan AJ, et al. Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed/refractory (Rel/Ref) classical Hodgkin lymphoma (cHL): initial results of a phase I/II trial. Blood 2016; 128: 1834.

Stamatoullas A, Ghesquieres H, Clement filliatre L, et al. Brentuximab vedotin in first refractory/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study. Blood 2019; 134(Suppl. 1): 132.

Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a children’s oncology group, multicentre single-arm, phase 1-2 trial. Lancet Oncol 2018; 19: 1229–1238.
109. Abuelgasim KA, Alzahrani M, Alsharhan Y, et al. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. Bone Marrow Transplant 2019; 54: 1168–1172.

110. Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018; 131: 1183–1194.

111. Moskowitz C. Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2016; 2016: 331–338.

112. Khan N and Moskowitz AJ. Where do the new drugs fit in for relapsed/refractory Hodgkin lymphoma? Curr Hematol Malig Rep 2017; 12: 227–233.

113. Hagenbeak A, Mooij H, Zijlstra J, et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the HOVON/LLPC transplant BRaVE study. Haematologica 2019; 104: e151–e153.

114. LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018; 132: 40–48.

115. O’Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol 2018; 19: 257–266.

116. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.

117. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol 1999; 17: 1244.

118. Advani RH, Moskowitz AJ, Bartlett NL, et al. Phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory classic Hodgkin lymphoma: part 3 (concurrent dosing) results and updated progression-free survival results from parts 1 and 2 (staggered dosing). Blood 2018; 132(Suppl. 1): 1635.

119. Diefenbach CS, Hong F, David K, et al. Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412). Hematol Oncol 2017; 35: 84–85.

120. Diefenbach CS, Hong F, Cohen JB, et al. Preliminary safety and efficacy of the combination of brentuximab vedotin and ipilimumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412). Blood 2015; 126: 585.

121. Diefenbach CS, Hong F, David KA, et al. Title: a phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412: Arms D and E). Blood 2016; 128: 1106.

122. Diefenbach C, Hong F, Ambinder RF, et al. A phase I study with an expansion cohort of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412). Blood 2016; 128(Suppl. 1): 679.

123. Diefenbach CS, Hong F, Ambinder R, et al. Extended follow-up of a phase I trial of ipilimumab, nivolumab and brentuximab vedotin in relapsed Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412). Hematol Oncol 2019; 37: 123–124.

124. Angelopoulou MK, Vassilakopoulos TP, Batsis I, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412: Arms G-I). Blood 2018; 132(Suppl. 1): 679.

125. Eyre TA, Phillips EH, Linton KM, et al. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. Br J Haematol 2017; 179: 471–479.

126. Pellegrini C, Broccoli A, Pulsoni A, et al. Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma. Oncotarget 2017; 8: 91703–91710.

127. Onishi M, Graf SA, Holmberg L, et al. Brentuximab vedotin administered to platinum-refractory, transplant-naive Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Hematol Oncol 2015; 33: 187–191.
128. Sasse S, Rothe A, Goergen H, et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2013; 54: 2144–2148.

129. Zinzani PL, Pellegrini C, Cantonetti M, et al. Brentuximab vedotin in transplant-naive relapsed/refractory Hodgkin lymphoma: experience in 30 patients. Oncologist 2015; 20: 1413–1416.

130. Sirohi B, Cunningham D, Powles R, et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish cooperative group. J Clin Oncol 2001; 19: 1395–1404.

131. Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 2008; 19: 1312–1319.

132. Angelopoulou MKV, Tsirkinidis TP, Tsimpou P, et al. High-dose therapy and autologous stem-cell transplantation (HDT/ASCT) in relapsed/refractory Hodgkin’s lymphoma. Outcome and prognostic factors. European Group for Blood and Bone Marrow Transplantation, March 21–24, Vienna, Austria, 2010, p. S255.

133. von Tresckow B, Morschhauser F, Szer J, et al. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem-cell transplant: final results after early trial discontinuation. Leuk Lymphoma 2017; 58: 222–225.

134. Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem-cell transplantation. Blood 2019; 134: 22–29.

135. Hellenic Society of Hematology. Hodgkin disease: General Secretary, Ministry of Health, Hellenic Republic, September 2018, http://www.moh.gov.gr/articles/health/domes-kai-drasisis-gia-thn-ygeia/articles/health/domes-kai-drasisis-gia-thn-ygeia/kwdikopoihseis/therapeutika-prwtokolla-syntagrofiashs/diagnostika-kai-therapeutika-prwtokolla-syntagrofiashs/5423-diaignwstika-kai-therapeutika-prwtokolla-syntagrofiashs-aimatologikwn-noshmatwn.

136. Hoppe TR, Advani RH, Ai WZ, et al. NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. J Natl Compr Canc Netw 2018; 16: 245–254.

137. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem-cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2006; 12: 1065–1072.

138. Montanari F and Diefenbach C. Relapsed Hodgkin lymphoma: management strategies. Curr Hematol Malig Rep 2014; 9: 284–293.

139. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem-cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625–633.

140. Dean RM, Sweetenham JW, Jin T, et al. Risk factors and outcomes for relapse after autologous stem-cell transplantation for Hodgkin lymphoma. Blood 2007; 110: 1903.

141. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem-cell transplant. Hematology Am Soc Hematol Educ Program 2008; 2008: 326–333.

142. Kaloyannidis P, Voutiadou G, Baltadakis I, et al. Outcomes of Hodgkin’s lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 451–457.

143. Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem-cell transplantation. Ann Oncol 2013; 24: 2430–2434.

144. Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem-cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009; 146: 158–163.

145. Anderlini P, Saliba RM, Lededsa C, et al. Gemcitabine, fludarabine, and melphalan for reduced-intensity conditioning and allogeneic stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2016; 22: 1333–1337.

146. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934–1941.

147. Sureda A, Canals C, Arranz R, et al. Allogeneic stem-cell transplantation after reduced intensity conditioning in patients with relapsed or
refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the lymphoma working party of the European group for blood and marrow transplantation. *Haematologica* 2012; 97: 310–317.

148. Chen R, Palmer JM, Popplewell L, et al. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. *Ann Hematol* 2011; 90: 803–818.

149. Younes A, Gopal AK, Smith SE. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. *J Clin Oncol* 2012; 30: 2183–2189.

150. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. *J Clin Oncol* 2007; 25: 571–578.

151. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. *Blood* 2015; 125: 1236–1243.

152. Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. *Blood* 2016; 128: 1562–1566.

153. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. *J Hematol Oncol* 2014; 7: 24.

154. Walewski J, Hellmann A, Siritanaratkul N, et al. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem-cell transplant or multi-agent chemotherapy. *Br J Haematol* 2018; 183: 400–410.

155. Salihoglu A, Elverdi T, Karadogan I, et al. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. *Ann Hematol* 2015; 94: 415–420.

156. Perrot A, Monjanel H, Bouabdallah R, et al. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French named-patient program. *Haematologica* 2016; 101: 466–473.

157. Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem-cell transplant in the current era of novel therapeutics: a retrospective analysis. *Am J Hematol* 2017; 92: 879–884.

158. Tsigiotis P, Vassilakopoulos T, Batsis I, et al. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem-cell transplantation: a nationwide analysis. *Hematol Oncol* 2018; 36: 645–650.

159. Brockelmann PJ, Zagadaiov EA and Corman SL. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are ineligible for autologous stem-cell transplant: a Germany and United Kingdom retrospective study. *Eur J Haematol* 2017; 99: 553–558.

160. Paydas S, Ogul A, Irii C, et al. Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma. *Ann Hematol* 2016; 95: 145–146.

161. Spathas N, Belia M, Giannikos T, et al. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma. JBUON 2019; 24: 2483–2489.

162. Gupta A, Petrasek J, Sen S, et al. Single-agent brentuximab as bridging therapy for Hodgkin lymphoma patients with hepatic impairment. *Clin Lymphoma Myeloma Leuk* 2016; 16: e11–e14.

163. Cheah CY, Chihara D, Horowitz S, et al. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. *Ann Oncol* 2016; 27: 1317–1323.

164. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. *N Engl J Med* 2015; 372: 311–319.

165. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. *J Clin Oncol* 2016; 34: 3733–3739.

166. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. *J Clin Oncol* 2018; 36: 1428–1439.

167. Cohen JB, Kuruvilla J, Engert A, et al. Nivolumab treatment beyond investigator-
assessed progression: extended follow-up in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 CheckMate 205 study. Blood 2018; 132(Suppl. 1): 2932.

168. Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017; 35: 2125–2132.

169. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, single-arm phase 2 trial. Lancet Oncol 2016; 17: 1283–1294.

170. Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087. Blood 2019; 134: 1144–1153.

171. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic cell transplantation and brentuximab vedotin: extended follow-up of the phase 2 single-arm CheckMate 205 study. Blood 2018; 132(Suppl. 1): 2897.

172. European Medical Agency. Opdivo (Nivolumab). Product information: Bristol-Myers Squibb S.r.l, Italy, https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf.

173. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059–3068.

174. Moskowitz CH, Chen RW, Armand P, et al. Pembrolizumab antitumor activity in relapsed/refractory classical Hodgkin lymphoma in KEYNOTE-087: revised response criteria for malignant lymphoma 2007 criteria versus Lugano 2014 classification. Blood 2017; 130(Suppl. 1): 4085.

175. Zinzani PL, Lee HJ, Armand P, et al. Three-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classic Hodgkin lymphoma. Blood 2019; 134(Suppl. 1): 240.

176. Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol 2019; 6: e12–e19.

177. Song Y, Gao Q, Zhang H, et al. Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: preliminary efficacy and safety results from a phase 2 study. Blood 2018; 132(Suppl. 1): 682.

178. Vassilakopulos TP, Chatzidimitriou C, Asimakopoulos JV, et al. Immunotherapy in Hodgkin lymphoma: present status and future strategies. Cancers (Basel) 2019; 11: 1071.

179. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016; 128: 2489–2496.

180. Dercle L, Seban RD, Lazarovici J, et al. 18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor. J Nucl Med 2018; 59: 15–24.

181. Falchi L, Sawas A, Deng C, et al. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. J Hematol Oncol 2016; 9: 132.

182. Nie J, Wang C, Liu Y, et al. Addition of Low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol 2019; 37: 1479–1489.

183. Rossi C, Gilhodes J, Maerevoet M, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after unsatisfactory response of anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a retrospective series from Lysa centers. Blood 2017; 130(Suppl. 1): 652.

184. Carreau NA, Pail O, Armand P, et al. Checkpoint blockade therapy may sensitize Hodgkin lymphoma to subsequent therapy. Blood 2018; 132(Suppl. 1): 1626.

185. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018; 36: 1714–1768.

186. Vardhana S, Cicero K, Velez MJ, et al. Strategies for recognizing and managing immune-mediated adverse events in the treatment of Hodgkin lymphoma with checkpoint inhibitors. Oncologist 2019; 24: 86–95.
187. Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. *Blood* 2017; 129: 2471–2478.

188. Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. *Blood* 2017; 130: 221–228.

189. Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. *Am J Hematol* 2010; 85: 320–324.

190. Johnston PB, Pinter-Brown LC, Warsi G, et al. Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma. *Exp Hematol Oncol* 2018; 7: 12.

191. Rocha T, Fortier SC, Fischer T, et al. Everolimus as a single agent in refractory or relapsed Hodgkin’s lymphoma: the Brazilian named patient program experience. *Rev Bras Hematol Hemoter* 2017; 39: 216–222.

192. von Tresckow B, Hüttmann A, Vucinic V, et al. Induction therapy with everolimus in combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in patients with relapsed or refractory classical Hodgkin lymphoma: a randomized, placebo-controlled phase I/II trial (HD-R3i). *Blood* 2018; 132(Suppl. 1): 2912.

193. Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. *Blood* 2011; 118: 5119–5125.

194. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. *J Clin Oncol* 2012; 30: 2197–2203.

195. Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. *Lancet Oncol* 2011; 12: 1222–1228.

196. Batlevi CL, Kasamon Y, Bociek RG, et al. ENGAGE-501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. *Haematologica* 2016; 101: 968–975.

197. Walewski J, Paszkiewicz-Kozik E, Borsaru G, et al. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study. *Leuk Lymphoma* 2019; 60: 675–684.

198. Van Den Neste E, Andre M, Gastinne T, et al. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. *Haematologica* 2018; 103: 840–848.

199. Gopal AK, Fanale MA, Moskowitz CH, et al. Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma. *Ann Oncol* 2017; 28: 1057–1063.

200. Pinto A, Pavone V, Angriulli F, et al. Lenalidomide in combination with bendamustine for patients with chemorefractory Hodgkin lymphoma: final results of the Leben multicenter phase 1/2 study. *Blood* 2015; 126: 1541.

201. Lemoine M, Derenzini E, Buglio D, et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. *Blood* 2012; 119: 4017–4025.

202. Christian B, Kopko A, Fehniger TA, et al. A phase I trial of the histone deacetylase (HDAC) inhibitor, panobinostat, in combination with lenalidomide in patients with relapsed/refractory Hodgkin’s lymphoma (HL). *Blood* 2012; 120: 1644.

203. Christian B, Wei L, Sexton J, et al. A phase I/II trial of the histone deacetylase (HDAC) inhibitor, panobinostat, in combination with lenalidomide in patients with relapsed/refractory Hodgkin’s lymphoma (HL). *Blood* 2014; 124: 3099.

204. Kirschbaum MH, Goldman BH, Zain JM, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest oncology group study S0517. *Leuk Lymphoma* 2012; 53: 259–262.

205. Younes A, Romaguera J, Fanale M, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. *J Clin Oncol* 2012; 30: 4161–4167.

206. Kim SJ, Kang HJ, Dong-Yeop S, et al. The efficacy of JAK2 inhibitor in heavily pretreated classical Hodgkin lymphoma: a prospective pilot study of ruxolitinib in relapsed or refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood* 2016; 128: 1820.

207. von Tresckow B. JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
208. Hamadani M, Balasubramanian S and Hari PN. Ibrutinib in refractory classic Hodgkin's lymphoma. *N Engl J Med* 2015; 373: 1381–1382.

209. Ramchandren R, Phillips TJ, Devata S, et al. A phase II multicenter single arm study of ibrutinib in patients with relapsed or refractory classical Hodgkin lymphoma. *Blood* 2017; 130(Suppl. 1): 1527.

210. Chen RW, Palmer JM, Herrera AF, et al. Phase II study of brentuximab vedotin plus ibrutinib for patients with relapsed/refractory Hodgkin lymphoma. *Blood* 2017; 130(Suppl. 1): 738.

211. Ramos CA, Ballard B, Liu E, et al. Chimeric T cells for therapy of CD30+ Hodgkin and Non-Hodgkin lymphomas. *Blood* 2015; 126: 185.

212. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. *J Clin Oncol* 2014; 32: 798–808.

213. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the lymphoma working party of the European group for blood and marrow transplantation. *J Clin Oncol* 2008; 26: 455–462.

214. Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem-cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. *Haematologica* 2009; 94: 230–238.

215. Phillips GL, Reece DE, Barnett MJ, et al. Allogeneic marrow transplantation for refractory Hodgkin’s disease. *J Clin Oncol* 1989; 7: 1039–1045.

216. Nachbar D, Oberaigner W, Fritsch E, et al. Allogeneic or autologous stem-cell transplantation (SCT) for relapsed and refractory Hodgkin’s disease and non-Hodgkin’s lymphoma: a single-centre experience. *Eur J Haematol* 2001; 66: 43–49.

217. Jones RJ, Piantadosi S, Mann RB, et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. *J Clin Oncol* 1990; 8: 527–537.

218. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. *J Clin Oncol* 1993; 11: 2342–2350.

219. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem-cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant-related mortality and impact of intensity of conditioning regimen. *Bone Marrow Transplant* 2005; 35: 943–951.

220. Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem-cell transplantation. *Bone Marrow Transplant* 2008; 41: 765–770.

221. Carella AM, Cavaliere M, Lemma E, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. *J Clin Oncol* 2000; 18: 3918–3924.

222. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem-cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. *Br J Haematol* 2007; 139: 70–80.

223. Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. *Blood* 2010; 115: 3671–3677.

224. Rashidi A, Ebadi M and Cashen AF. Allogeneic hematopoietic stem-cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. *Bone Marrow Transplant* 2016; 51: 521–528.

225. Marais A, Porcher R, Robin M, et al. Impact of disease status and stem-cell source on the results of reduced intensity conditioning transplant for Hodgkin’s lymphoma: a retrospective study from the French society of bone marrow transplantation and cellular therapy (SFGM-TC). *Haematologica* 2013; 98: 1467–1475.

226. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. *Bone Marrow Transplant* 2015; 50: 1037–1056.
227. Peggs KS. Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT? Blood Adv 2018; 2: 817–820.

228. Chen R, Palmer JM, Tsai NC, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 2014; 20: 1864–1868.

229. Reyal Y, Kayani I, Bloor AJC, et al. Impact of pretransplantation 18F-fluorodeoxyglucose-positron emission tomography on survival outcomes after T cell-depleted allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 2016; 22: 1234–1241.

230. Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem-cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood 2017; 129: 1380–1388.

231. Armand P, Zinzani PL, Collins GP, et al. Outcomes of allogeneic hematopoietic stem-cell transplantation (HSCT) after treatment with nivolumab for relapsed/refractory Hodgkin lymphoma. Blood 2016; 128: 3502.

232. Herbaux C, Merryman R, Devine S, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood 2018; 132: 9–16.

233. Castagna L, Bramanti S, Devillier R, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplant 2017; 52: 683–688.

234. Burroughs LM, O’Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1279–1287.

235. Raiola A, Dominietto A, Varaldo R, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transplant 2014; 49: 190–194.